[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4816
1. Lallana Álvarez MJ, Rabanaque Hernández MJ: [Variability in the Use of New Drugs in a Primary Care District]. Rev Esp Salud Publica; 2005 Jun 01;79:379-389

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Variability in the Use of New Drugs in a Primary Care District].
  • [Transliterated title] Variabilidad en la utilización de nuevos medicamentos en un área de atención primaria.
  • This study is aimed at ascertaining the degree to which pharmaceutical novelties are being used in one healthcare district in Zaragoza, describing which are those most used and the trend thereof over the course of time in addition to analyzing the characteristics of those centers associated with a greater use of these drugs.
  • The percentage of use of novelties throughout the first year these drugs were marketed at each primary care center was calculated, the characteristics of those centers associated with a greater degree of innovation having been analyzed.
  • The percentage of use of new drugs as compared to all of the drugs prescribed at the healthcare centers studied fell within the 0.3% -1.18% range.
  • In the analysis made by centers, the «per-patient expense» and the «consultations per physician» are positively correlated with a greater use of new drugs, whilst the percentage of retirees showed a reverse ratio.
  • CONCLUSIONS: A high degree of variability exists in the percentage of use of pharmaceutical novelties among the primary care centers.
  • The centers having the largest number of consultations per physician are those tending toward more readily incorporating these new drugs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28272386.001).
  • [ISSN] 2173-9110
  • [Journal-full-title] Revista espanola de salud publica
  • [ISO-abbreviation] Rev. Esp. Salud Publica
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Drug utilization / Primary health care
  •  go-up   go-down


2. Ródenas F, Garcés J, Carretero S, Megia MJ: Case management method applied to older adults in the primary care centres in Burjassot (Valencian Region, Spain). Eur J Ageing; 2008 Mar;5(1):57-66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case management method applied to older adults in the primary care centres in Burjassot (Valencian Region, Spain).
  • This research determines if the case management for health primary care means changes in: (a) frequency of use of social and health care resources, (b) number of patients visiting a doctor or social worker in the primary care centre, and visits that these professionals receive, (c) number of drugs consumed, (d) urgent hospital admittances which did not need significant intervention and (e) patients' and caregivers' satisfaction towards the social and health care resources received.
  • One hundred and fifty-two older dependent patients receiving home care in 2004, in a health department of the Valencia Region (Spain) collaborated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 33.3% of the patients in the intervention group versus 60.0% in the control group were admitted by the emergency room service for treatment that did not require surgery, but the difference is not significant; (d) 55.5% of these patients were very much satisfied with the care received and the benefits of the health care resources they had used versus 29.4% in the control group, showing a significant difference, 56.5% of the informal caregivers of patients in the intervention group were satisfied with the health care resources received by their family members, against 31.9% in control group.
  • [Cites] Health Soc Care Community. 2000 Jul;8(4):242-250 [11560694.001]
  • [Cites] Int J Geriatr Psychiatry. 2007 Aug;22(8):738-49 [17171750.001]
  • [Cites] Aging Clin Exp Res. 2004 Aug;16(4):259-69 [15575119.001]
  • [Cites] Gerontologist. 1980 Dec;20(6):649-55 [7203086.001]
  • [Cites] Health Policy. 2003 Sep;65(3):201-15 [12941489.001]
  • [Cites] J Am Geriatr Soc. 2007 Feb;55(2):166-74 [17302651.001]
  • [Cites] Md State Med J. 1965 Feb;14:61-5 [14258950.001]
  • [Cites] Care Manag J. 2002 Spring;3(3):113-9 [12632877.001]
  • [Cites] Gerontologist. 1969 Autumn;9(3):179-86 [5349366.001]
  • [Cites] Health Soc Care Community. 2004 Nov;12(6):466-74 [15717894.001]
  • [Cites] BMJ. 2007 Jan 6;334(7583):31 [17107984.001]
  • [Cites] Health Care Financ Rev. 2002 Fall;24(1):63-82 [12545599.001]
  • [Cites] Health Policy. 2006 Jan;75(2):121-30 [16226336.001]
  • [Cites] Age Ageing. 2001 Sep;30(5):409-13 [11709380.001]
  • (PMID = 28798562.001).
  • [ISSN] 1613-9372
  • [Journal-full-title] European journal of ageing
  • [ISO-abbreviation] Eur J Ageing
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Case management / Dependency / Older adults / Primary care
  •  go-up   go-down


3. Korpershoek E, Stobbe CK, van Nederveen FH, de Krijger RR, Dinjens WN: Intra-tumoral molecular heterogeneity in benign and malignant pheochromocytomas and extra-adrenal sympathetic paragangliomas. Endocr Relat Cancer; 2010 Sep;17(3):653-62
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-tumoral molecular heterogeneity in benign and malignant pheochromocytomas and extra-adrenal sympathetic paragangliomas.
  • Pheochromocytomas (PCCs) and extra-adrenal sympathetic paragangliomas (sPGLs) are catecholamine-producing tumors occurring in the context of hereditary tumor syndromes, with known germline mutations, and as sporadic tumors.
  • The pathogenesis of sporadic PCC and sPGL is poorly understood, and little is known about intra-tumoral heterogeneity with respect to molecular aberrations.
  • Since knowledge on intra-tumoral heterogeneity is important for understanding the pathogenesis of these tumors, we investigated 12 benign and 8 malignant PCCs and sPGLs for loss of heterozygosity (LOH) on DNA extracted from different regions of each tumor and from metastases.
  • LOH markers were selected on chromosomal regions frequently deleted in PCC, including 1p, 3q, 3p, and 11p.
  • In addition, differences in LOH patterns were detected between paired primary malignant tumors, and their metastases and different LOH patterns were observed in bilateral PCC of a multiple endocrine neoplasia type 2 patient.
  • We demonstrate that malignant PCC and sPGL have more intra-tumoral molecular heterogeneity than benign tumors, which suggests that benign and malignant PCC and sPGL have a different pathogenesis.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Chromosomes, Human. Loss of Heterozygosity. Paraganglioma / genetics. Pheochromocytoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. DNA, Neoplasm / genetics. Female. Genetic Variation. Histocytochemistry. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20488782.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


Advertisement
4. Jiang H, Rao KS, Yee VC, Kraus JP: Characterization of four variant forms of human propionyl-CoA carboxylase expressed in Escherichia coli. J Biol Chem; 2005 Jul 29;280(30):27719-27
Hazardous Substances Data Bank. BIOTIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Propionyl-CoA carboxylase (PCC) is a biotin-dependent mitochondrial enzyme that catalyzes the conversion of propionyl-CoA to D-methylmalonyl-CoA.
  • PCC consists of two heterologous subunits, alpha PCC and beta PCC, which are encoded by the nuclear PCCA and PCCB genes, respectively.
  • Deficiency of PCC results in a metabolic disorder, propionic acidemia, which is sufficiently severe to cause neonatal death.
  • We have purified three PCCs containing pathogenic mutations in the beta subunit (R165W, E168K, and R410W) and one PCCB polymorphism (A497V) to homogeneity to elucidate the potential structural and functional effects of these substitutions.
  • The three mutant PCCs had half the catalytic efficiency of wild-type PCC as judged by the kcat/Km ratios.
  • However, the variant PCCs were less thermostable than the wild-type.
  • Our biochemical data and the structural analysis using a beta PCC homology model indicate that the pathogenic nature of these mutations is more likely to be due to a lack of assembly rather than disruption of catalysis.
  • The strong favorable effect of the co-expressed chaperone proteins on PCC folding, assembly, and activity suggest that propionic acidemia may be amenable to chaperone therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890657.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / P01HD08315
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acyl Coenzyme A; 0 / Recombinant Proteins; 1264-45-5 / methylmalonyl-coenzyme A; 317-66-8 / propionyl-coenzyme A; 6SO6U10H04 / Biotin; EC 4.1.1.41 / Methylmalonyl-CoA Decarboxylase
  •  go-up   go-down


5. Wallis L: Anewline in men's talk. Nurs Stand; 2005 Jan 19;19(19):16-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ' Ms Spickett is a urology nurse specialist who works for the Prostate Cancer Charity (PCC).
  • Based in London, she is one of a team of six nurses who staff the helpline.
  • She is talking to the wife of a man in the final stages of terminal prostate cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28006525.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Korpershoek E, Petri BJ, van Nederveen FH, Dinjens WN, Verhofstad AA, de Herder WW, Schmid S, Perren A, Komminoth P, de Krijger RR: Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma. Endocr Relat Cancer; 2007 Jun;14(2):453-62
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma.
  • Pheochromocytomas (PCCs) are rare tumors that arise from chromaffin tissue in the adrenal medulla, but can also occur in the abdomen outside the adrenals and are then called sympathetic paragangliomas (sPGLs).
  • According to the literature, between 15 and 25% of apparently sporadic adrenal PCC and sPGL are caused by germline mutations in RET, von Hippel-Lindau disease (VHL), succinate dehydrogenase subunit B (SDHB), or subunit D SDHD.
  • However, few studies have addressed the mutationfrequency of these candidate genes in selected subgroups of PCC andsPGL, such as bilateral adrenal PCC or extra-adrenal sPGL, and none have looked at somatic mutations by analyzing tumor tissue.
  • Therefore, we have investigated the occurrence of germline and somatic mutations in RET, VHL, SDHB, and SDHD in comparatively large series of bilateral adrenal PCC (n = 33 patients) and sPGL (n = 26 patients), with the aim of determining the mutation frequency of each of these genes and to establish a genetic testing algorithm.
  • Twenty-one RET, two VHL germline, and one SDHD mutations were found in the patients with bilateral adrenal PCC.
  • We conclude that germline RET mutations are predominantly found in bilateral PCC, and that somatic and germline SDHB and SDHD mutations usually occur in sPGL, which has practical consequences for genetic testing algorithms.
  • We suggest that sequential mutation analysis should be directed first at RET, followed by VHL and SDHD for patients with bilateral adrenal PCC at diagnosis, and at SDHB and SDHD for patients with sPGL.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Genes, Neoplasm. Paraganglioma / genetics. Pheochromocytoma / genetics
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Animals. Cattle. DNA Mutational Analysis. Female. Germ-Line Mutation. Humans. Iron-Sulfur Proteins / genetics. Male. Mice. Middle Aged. Molecular Sequence Data. Mutation. Proto-Oncogene Proteins c-ret / genetics. Rats. Succinate Dehydrogenase / genetics. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639058.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iron-Sulfur Proteins; 0 / SDHD protein, human; EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


7. Tonks ID, Mould AW, Schroder WA, Cotterill A, Hayward NK, Walker GJ, Kay GF: Dual loss of rb1 and Trp53 in the adrenal medulla leads to spontaneous pheochromocytoma. Neoplasia; 2010 Mar;12(3):235-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual loss of rb1 and Trp53 in the adrenal medulla leads to spontaneous pheochromocytoma.
  • Using a Cre/loxP system, we have determined the phenotypic consequences attributable to in vivo deletion of both Rb1 and Trp53 in the mouse adrenal medulla.
  • The coablation of these two tumor suppressor genes during embryogenesis did not disrupt adrenal gland development but resulted in the neoplastic transformation of the neural crest-derived adrenal medulla, yielding pheochromocytomas (PCCs) that developed with complete penetrance and were inevitably bilateral.
  • Despite their typically benign status, these PCCs had profound ramifications on mouse vitality, with effected mice having a median survival of only 121 days.
  • Evaluation of these PCCs by both immunohistochemistry and electron microscopy revealed that most Rb1(-/-):Trp53(-/-) chromaffin cells possessed atypical chromagenic vesicles that did not seem capable of appropriately storing synthesized catecholamines.
  • The structural remodeling of the heart in mice harboring Rb1(-/-):Trp53(-/-) PCCs suggests that the mortality of these mice may be attributable to the inappropriate release of catecholamines from the mutated adrenal chromaffin cells.
  • On the basis of the collective data from Rb1 and Trp53 knockout mouse models, it seems that the conversion of Rb1 loss-driven adrenal medulla hyperplasia to PCC can be greatly enhanced by the compound loss of Trp53, whereas the loss of Trp53 alone is generally ineffectual on adrenal chromaffin cell homeostasis.
  • Consequently, the Trp53 tumor suppressor gene is an efficient genetic modifier of Rb1 loss in the development of PCC, and their compound loss in the adrenal medulla has a profound impact on both cellular homeostasis and animal vitality.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Genes, p53 / physiology. Pheochromocytoma / pathology. Retinoblastoma Protein / physiology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2001 Jun;54(6):443-8 [11376017.001]
  • [Cites] J Neurosci. 2001 Feb 15;21(4):1110-6 [11160381.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1455-60 [11818530.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3803-11 [12097293.001]
  • [Cites] Mol Cell Biol. 2003 Feb;23(3):1044-53 [12529408.001]
  • [Cites] J Pathol. 2003 Jul;200(3):375-82 [12845634.001]
  • [Cites] Genesis. 2003 Nov;37(3):131-8 [14595836.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1235-43 [15026807.001]
  • [Cites] Cancer. 1977 Nov;40(5):1987-2004 [922654.001]
  • [Cites] J Neurosci Methods. 1980 Oct;3(1):1-5 [6164878.001]
  • [Cites] Scanning Microsc. 1988 Mar;2(1):503-12 [3368774.001]
  • [Cites] Hypertension. 1991 Nov;18(5 Suppl):III35-9 [1657774.001]
  • [Cites] Cell. 1992 Apr 17;69(2):265-73 [1568246.001]
  • [Cites] Nature. 1992 Apr 23;356(6371):713-5 [1570015.001]
  • [Cites] J Endocrinol Invest. 1992 Oct;15(9):651-63 [1479148.001]
  • [Cites] Curr Biol. 1994 Jan 1;4(1):1-7 [7922305.001]
  • [Cites] EMBO J. 1994 Sep 15;13(18):4251-9 [7925270.001]
  • [Cites] EMBO J. 1994 Sep 15;13(18):4260-8 [7925271.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):480-4 [7951317.001]
  • [Cites] Oncogene. 1995 Jul 20;11(2):325-35 [7624147.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):144-8 [8563751.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6933-8 [9192669.001]
  • [Cites] Genes Dev. 1998 Jun 1;12(11):1599-609 [9620848.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5284-90 [9710613.001]
  • [Cites] EMBO J. 1999 Mar 15;18(6):1571-83 [10075928.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3916-21 [10097138.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2577-80 [10363976.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Genes Dev. 2004 Dec 1;18(23):2952-62 [15574596.001]
  • [Cites] Fam Cancer. 2005;4(1):17-23 [15883706.001]
  • [Cites] Pigment Cell Res. 2005 Aug;18(4):252-64 [16029419.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4564-76 [16738322.001]
  • [Cites] Science. 2006 Jun 16;312(5780):1650-3 [16728594.001]
  • [Cites] Pigment Cell Res. 2006 Aug;19(4):260-83 [16827746.001]
  • [Cites] Cell. 2006 Jul 14;126(1):107-20 [16839880.001]
  • [Cites] Cell Cycle. 2006 Sep;5(18):2054-6 [16969113.001]
  • [Cites] Oncogene. 2007 Jan 25;26(4):554-70 [16953232.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):160-5 [17427103.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):407-13 [18223555.001]
  • [Cites] Endocr Relat Cancer. 2008 Jun;15(2):609-21 [18509008.001]
  • [Cites] Neoplasia. 2008 Nov;10(11):1213-21 [18953430.001]
  • [Cites] J Invest Dermatol. 2009 Jan;129(1):184-93 [18633434.001]
  • [Cites] Biochim Biophys Acta. 2009 May;1787(5):328-34 [19413947.001]
  • [Cites] Science. 2009 May 22;324(5930):1029-33 [19460998.001]
  • [Cites] Pigment Cell Melanoma Res. 2009 Jun;22(3):328-30 [19243574.001]
  • [Cites] PLoS One. 2009;4(9):e7094 [19763184.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):372-82 [10667590.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):383-9 [10667591.001]
  • [Cites] Curr Biol. 2000 May 4;10(9):543-6 [10801445.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6147-58 [10913196.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10826-31 [10995476.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):222-4 [11175795.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):418-25 [11694875.001]
  • (PMID = 20234817.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Catecholamines; 0 / Retinoblastoma Protein; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ PMC2838441
  •  go-up   go-down


8. Meredith LS, Eisenman DP, Green BL, Basurto-Dávila R, Cassells A, Tobin J: System factors affect the recognition and management of posttraumatic stress disorder by primary care clinicians. Med Care; 2009 Jun;47(6):686-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] System factors affect the recognition and management of posttraumatic stress disorder by primary care clinicians.
  • BACKGROUND: Posttraumatic stress disorder (PTSD) is common with an estimated prevalence of 8% in the general population and up to 17% in primary care patients.
  • Yet, little is known about what determines primary care clinician's (PCC's) provision of PTSD care.
  • OBJECTIVE: To describe PCC's reported recognition and management of PTSD and identify how system factors affect the likelihood of performing clinical actions with regard to patients with PTSD or "PTSD treatment proclivity."
  • DESIGN: Linked cross-sectional surveys of medical directors and PCCs.
  • PARTICIPANTS: Forty-six medical directors and 154 PCCs in community health centers (CHCs) within a practice-based research network in New York and New Jersey.
  • MEASUREMENTS: Two system factors (degree of integration between primary care and mental health services, and existence of linkages with other community, social, and legal services) as reported by medical directors, and PCC reports of self-confidence, perceived barriers, and PTSD treatment proclivity.
  • RESULTS: Surveys from 47 (of 58) medical directors (81% response rate) and 154 PCCs (86% response rate).
  • PCCs from CHCs with better mental health integration reported greater confidence, fewer barriers, and higher PTSD treatment proclivity (all P < 0.05).
  • The PCCs in CHCs with better community linkages reported greater confidence, fewer barriers, higher PTSD treatment proclivity, and lower proclivity to refer patients to mental health specialists or to use a "watch and wait" approach (all P < 0.05).
  • CONCLUSIONS: System factors play an important role in PCC PTSD management.
  • Interventions are needed that restructure primary care practices by making mental health services more integrated and community linkages stronger.

  • MedlinePlus Health Information. consumer health - Post-Traumatic Stress Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2000 Jan 12;283(2):212-20 [10634337.001]
  • [Cites] J Ambul Care Manage. 1998 Apr;21(2):20-9; discussion 43-55 [10181462.001]
  • [Cites] Gen Hosp Psychiatry. 2000 Jul-Aug;22(4):261-9 [10936633.001]
  • [Cites] Arch Fam Med. 2000 Sep-Oct;9(9):802-10 [11031385.001]
  • [Cites] Health Care Manage Rev. 2000 Fall;25(4):9-17 [11072628.001]
  • [Cites] J Gen Intern Med. 2000 Dec;15(12):868-77 [11119183.001]
  • [Cites] Arch Intern Med. 2001 Jan 8;161(1):85-91 [11146702.001]
  • [Cites] J Fam Pract. 2001 Jan;50(1):41-7 [11195480.001]
  • [Cites] J Health Care Poor Underserved. 2001 Feb;12(1):103-12 [11217223.001]
  • [Cites] Jt Comm J Qual Improv. 2001 Feb;27(2):63-80 [11221012.001]
  • [Cites] Pediatr Emerg Care. 2003 Feb;19(1):15-9 [12592107.001]
  • [Cites] J Trauma Stress. 2003 Feb;16(1):5-16 [12602647.001]
  • [Cites] Psychiatr Q. 2003 Spring;74(1):45-60 [12602788.001]
  • [Cites] Arch Gen Psychiatry. 2003 Apr;60(4):369-74 [12695314.001]
  • [Cites] JAMA. 2003 Jun 18;289(23):3145-51 [12813120.001]
  • [Cites] JAMA. 2003 Aug 6;290(5):627-34 [12902366.001]
  • [Cites] Psychiatr Serv. 2004 Apr;55(4):415-20 [15067154.001]
  • [Cites] JAMA. 1992 Jun 17;267(23):3157-60 [1593735.001]
  • [Cites] Arch Intern Med. 1992 Jun;152(6):1186-90 [1599346.001]
  • [Cites] Arch Fam Med. 1994 Dec;3(12):1065-72 [7804491.001]
  • [Cites] JAMA. 1995 Apr 5;273(13):1026-31 [7897786.001]
  • [Cites] J Subst Abuse Treat. 1999 Jan;16(1):71-80 [9888124.001]
  • [Cites] J Gen Intern Med. 1999 Jan;14(1):39-48 [9893090.001]
  • [Cites] J Behav Health Serv Res. 1999 Feb;26(1):80-94 [10069143.001]
  • [Cites] J Am Med Womens Assoc. 1999 Spring;54(2):85-90 [10319597.001]
  • [Cites] JAMA. 1999 Aug 4;282(5):468-74 [10442663.001]
  • [Cites] Gen Hosp Psychiatry. 2005 May-Jun;27(3):169-79 [15882763.001]
  • [Cites] Arch Gen Psychiatry. 2005 Jun;62(6):617-27 [15939839.001]
  • [Cites] Gen Hosp Psychiatry. 2005 Nov-Dec;27(6):392-9 [16271653.001]
  • [Cites] Psychiatr Clin North Am. 2005 Dec;28(4):1079-92 [16325741.001]
  • [Cites] Psychiatr Serv. 2006 Jan;57(1):48-55 [16399962.001]
  • [Cites] Diabetes Care. 2006 Feb;29(2):265-70 [16443871.001]
  • [Cites] Psychiatr Serv. 2006 Dec;57(12):1726-30 [17158486.001]
  • [Cites] J Gen Intern Med. 2007 Jun;22(6):719-26 [17503105.001]
  • [Cites] South Med J. 2007 Aug;100(8):797-802 [17713306.001]
  • [Cites] Gen Hosp Psychiatry. 2007 Sep-Oct;29(5):379-87 [17888803.001]
  • [Cites] J Trauma Stress. 2008 Apr;21(2):218-22 [18404649.001]
  • [Cites] Psychol Med. 2001 Apr;31(3):555-60 [11305864.001]
  • [Cites] Arch Gen Psychiatry. 2001 Jul;58(7):696-703 [11448378.001]
  • [Cites] JAMA. 2001 Sep 19;286(11):1325-30 [11560537.001]
  • [Cites] Gen Hosp Psychiatry. 2001 Nov-Dec;23(6):311-8 [11738461.001]
  • [Cites] JAMA. 2002 Dec 11;288(22):2836-45 [12472325.001]
  • [Cites] Arch Gen Psychiatry. 1995 Dec;52(12):1048-60 [7492257.001]
  • [Cites] Arch Gen Psychiatry. 1996 Oct;53(10):924-32 [8857869.001]
  • [Cites] J Clin Psychiatry. 1997;58 Suppl 9:33-6 [9329450.001]
  • [Cites] Ann Intern Med. 1997 Dec 15;127(12):1097-102 [9412313.001]
  • [Cites] Psychosomatics. 2000 May-Jun;41(3):245-52 [10849457.001]
  • (PMID = 19433999.001).
  • [ISSN] 1537-1948
  • [Journal-full-title] Medical care
  • [ISO-abbreviation] Med Care
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / MH070683-01A1; United States / NIMH NIH HHS / MH / R34 MH070683; United States / NIMH NIH HHS / MH / R34 MH070683-01A1; United States / NIMH NIH HHS / MH / R34MH070683
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS114528; NLM/ PMC2762995
  •  go-up   go-down


9. Lee CL, Wahnishe H, Sayre GA, Cho HM, Kim HJ, Hernandez-Pampaloni M, Hawkins RA, Dannoon SF, VanBrocklin HF, Itsara M, Weiss WA, Yang X, Haas-Kogan DA, Matthay KK, Seo Y: Radiation dose estimation using preclinical imaging with I124-metaiodobenzylguanidine (MIBG) PET. Med Phys; 2010 Sep;37(9):4861-4867

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: A pretherapyI124-metaiodobenzylguanidine (MIBG) positron emission tomography (PET)/computed tomography (CT) provides a potential method to estimate radiation dose to normal organs, as well as tumors prior to I131-MIBG treatment of neuroblastoma or pheochromocytoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524557.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Cancer / Computed tomography / Dosimetry / Heart / Liver / Medical imaging / PET / Positron emission tomography / Positron emission tomography (PET) / Radioactivity / Registration / Tissues / dosimetry / image registration / iodine-124 / metaiodobenzylguanidine (MIBG) / neuroblastoma / positron emission tomography / tumours
  •  go-up   go-down


10. Jeck-Thole S, Wagner W: Betahistine : A Retrospective Synopsis of Safety Data. Drug Saf; 2006 Nov;29(11):1049-1059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Betahistine is a structural analogue of histamine that is prescribed for the treatment of vestibular disorders such as Ménière's disease and the symptomatic treatment of vertigo.
  • Betahistine was reported to be involved in one anaphylactoid reaction and one case of Stevens-Johnson syndrome.
  • ADRs related to the nervous system predominantly reveal heterogeneous events that are not suggestive of a specific adverse reaction profile for betahistine.
  • A total of three cases of neoplasm have been reported.
  • An undiagnosed phaeochromocytoma was suspected.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28357699.001).
  • [ISSN] 1179-1942
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  •  go-up   go-down


11. Maĭstrenko NA, Romashchenko PN, Priadko AS, Vedeneeva LF, Markin SM: [The diagnosis and treatment of chromaffinomas]. Vestn Khir Im I I Grek; 2005;164(4):31-40
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The diagnosis and treatment of chromaffinomas].
  • The results of examinations and surgical treatment of 117 patients with chromaffin tumors are shown: one-sided localization in the adrenal in 88% of the patients, bilateral localization in 4.3%, and extraadrenal in 7.7%.
  • An analysis of the possibilities of the laboratory-instrumental diagnosis of chromaffinomas has shown that the method should be used in case of valid need.
  • The absence of changes to the level of catecholamines and their metabolites in urine does not exclude the presence of chromaffinomas.
  • The optimal access for the ablation of chromaffinoma of the adrenal larger than 5 cm in diameter is thoracofrenotomy in the tenth intercostal space.
  • Endovideosurgical interventions in the adrenals can be used for the size of chromaffinoma less than 5 cm in diameter and with the absence of signs of malignisation and marked hemodynamic disorders.
  • The superior medial laparotomy is expedient for extraadrenal pheochromocytoma of the abdominal area and for bilateral localization in the adrenals.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / surgery. Pheochromocytoma / diagnosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755734.001).
  • [ISSN] 0042-4625
  • [Journal-full-title] Vestnik khirurgii imeni I. I. Grekova
  • [ISO-abbreviation] Vestn. Khir. Im. I. I. Grek.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Catecholamines
  •  go-up   go-down


12. Lemeta S, Salmenkivi K, Pylkkänen L, Sainio M, Saarikoski ST, Arola J, Heikkilä P, Haglund C, Husgafvel-Pursiainen K, Böhling T: Frequent loss of heterozygosity at 6q in pheochromocytoma. Hum Pathol; 2006 Jun;37(6):749-54
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent loss of heterozygosity at 6q in pheochromocytoma.
  • Multiple genetic alterations have been associated with pheochromocytoma (PCC).
  • Most PCCs are sporadic, but they also occur in inherited tumor syndromes, including von Hippel-Lindau disease.
  • Although the etiology of most inherited PCCs is well documented, little is known about the etiology of sporadic tumors.
  • Mutations of those genes that harbor germ-line mutations in familial cases cover only 10% to 15% of somatic mutations in sporadic PCCs.
  • A previous cytogenetic analysis indicated frequent loss of 6q in sporadic PCCs.
  • We therefore investigated in detail 18 PCCs using 22 microsatellite markers spanning 6q to search for the presence of allele deletions and identify specific regions likely to contain tumor suppressor genes involved in PCC.
  • Moreover, we sought to compare PCC with capillary hemangioblastoma, another von Hippel-Lindau disease-associated tumor that we previously found to harbor frequent loss of heterozygosity (LOH) at 6q.
  • Our study revealed a high frequency (13/18; 72%) of overall 6q LOH in PCCs.
  • Altogether, for all 6q23-25 markers, including the ZAC1-specific ones, LOH or allelic imbalance was observed in 50% (9/18) of the PCCs.
  • Similar to our findings for capillary hemangioblastomas, our data for the first time suggest that one or several tumor suppressor genes located at 6q, particularly at 6q23-24, may play a role in the tumorigenesis of PCCs.
  • [MeSH-major] Allelic Imbalance. Cell Cycle Proteins / genetics. Chromosomes, Human, Pair 6. Loss of Heterozygosity. Pheochromocytoma / genetics. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Alleles. DNA, Neoplasm / analysis. Female. Gene Deletion. Genetic Markers. Hemangioblastoma / genetics. Hemangioblastoma / pathology. Humans. Male. Microsatellite Repeats. Middle Aged. Tumor Burden

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733217.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / Genetic Markers; 0 / PLAGL1 protein, human; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


13. Korpershoek E, Van Nederveen FH, Dannenberg H, Petri BJ, Komminoth P, Perren A, Lenders JW, Verhofstad AA, De Herder WW, De Krijger RR, Dinjens WN: Genetic analyses of apparently sporadic pheochromocytomas: the Rotterdam experience. Ann N Y Acad Sci; 2006 Aug;1073:138-48
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic analyses of apparently sporadic pheochromocytomas: the Rotterdam experience.
  • Pheochromocytomas (PCCs) are neuroendocrine tumors of chromaffin tissue that produce catecholamines.
  • They are usually located in the adrenal medulla, although in about 10% the tumors arise from extra-adrenal chromaffin tissue.
  • The majority of PCCs arise sporadically, but PCCs occur also in the context of hereditary cancer syndromes.
  • Familial PCC is inherited as an autosomal dominant trait alone or as a component of the multiple endocrine neoplasia Type 2 (MEN2) syndrome (RET gene), Von Hippel-Lindau (VHL) disease (VHL gene), neurofibromatosis Type 1 (NF1 gene), or familial pheochromocytoma-paraganglioma (PCC-PGL) syndrome (SDHD/B and C genes).
  • It has been reported that 24% of apparently sporadic PCCs patients harbor germline mutations in these PCC-causing genes.
  • We investigated the contribution of the inherited PCC-causing genes in a partly retrospectively and partly prospectively obtained series of 213 apparently sporadic PCCs.
  • In total we found germline mutations in about 7.5% of the investigated apparently sporadic PCCs.
  • Although 7.5% germline mutations in a series of apparently sporadic PCCs are far less than the more than 20% reported in the literature, the figure is significant enough to consider germline mutation testing for each patient with PCC.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Pheochromocytoma / genetics
  • [MeSH-minor] Genetic Predisposition to Disease. Germ-Line Mutation. Humans. Polymerase Chain Reaction. Proto-Oncogene Proteins c-ret / genetics. Succinate Dehydrogenase / genetics. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102080.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.3.99.1 / Succinate Dehydrogenase; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


14. Korpershoek E, Loonen AJ, Corvers S, van Nederveen FH, Jonkers J, Ma X, Ziel-van der Made A, Korsten H, Trapman J, Dinjens WN, de Krijger RR: Conditional Pten knock-out mice: a model for metastatic phaeochromocytoma. J Pathol; 2009 Mar;217(4):597-604
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditional Pten knock-out mice: a model for metastatic phaeochromocytoma.
  • Phaeochromocytomas (PCCs) are neuro-endocrine tumours of the adrenal medulla that are usually benign, but approximately 10% of patients develop metastases.
  • Malignant PCCs can only be diagnosed with certainty if metastases are present.
  • Here we describe adrenal tumours generated in a Pten conditional knock-out (KO) mouse model.
  • We characterized the molecular alterations in these tumours and compared them with human PCC.
  • Thirty-two of 41 (78%) male Psa-Cre;Pten-loxP/loxP mice presented adrenal tumours that were shown to be PCC by histology and by immunohistochemical staining for enzymes in the catecholamine biosynthetic pathway.
  • In 6 of 17 investigated mice, histological and immunohistochemical evidence was obtained for the presence of PCC lung metastases.
  • Array comparative genomic hybridization (CGH) analysis of the primary tumours showed loss of chromosomes 6 and 19, which are syntenic to human 3p and 11q.
  • The molecular aberrations in the mouse model corresponded to the alterations found in a subtype of human PCC, suggesting that the PCC of the Pten KO mice might be representative of human PCC.
  • The mouse model should allow further studies into the pathogenesis of human malignant PCCs and into therapeutic strategies for these tumours.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Disease Models, Animal. Lung Neoplasms / secondary. Neoplasm Proteins / genetics. PTEN Phosphohydrolase / genetics. Pheochromocytoma / secondary


15. Lai EW, Rodriguez OC, Aventian M, Cromelin C, Fricke ST, Martiniova L, Lubensky IA, Lisanti MP, Picard KL, Powers JF, Tischler AS, Pacak K, Albanese C: ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice. Cell Cycle; 2007 Aug 1;6(15):1946-50
SciCrunch. The Antibody Registry: Reagent: Antibodies .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice.
  • Pheochromocytoma (PCC) is a rare catecholamine-producing tumor that arises from the adrenal medulla and is often familial.
  • The genetic basis for familial PCC involves mutations of RET, VHL, SHDx or NF-1 in more than 20% of cases.
  • Additional genes may be important in pathogenesis of both familial and sporadic PCC.
  • ErbB-2/Her2/Neu is a growth factor receptor tyrosine kinase that is frequently overexpressed in tumors and there is clinical evidence suggesting that enhanced ErbB-2 growth factor receptor signaling may play a role in PCC.
  • In the present study, ectopic expression of an activated ErbB-2 transgene resulted in bilateral adrenal PCC.
  • Analyses of tumor samples and normal adrenal tissue revealed that levels of the Pten tumor suppressor protein were greatly reduced in PCCs, while levels of the cell cycle regulatory protein cyclin D1 were usually increased.
  • In addition, levels of phospo-AKT were increased in PCCs versus normal adrenal tissue.
  • Biochemical analyses established that PCC's were functionally active, producing abundant levels of the catecholamines, epinephrine and norepinephrine.
  • These data establish that increased ErbB-2 growth factor receptor signaling in the adrenal medulla can lead to PCC through combined influences on Pten, AKT andcyclin D1.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Adrenal Gland Neoplasms / pathology. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Pheochromocytoma / metabolism. Pheochromocytoma / pathology. Receptor, ErbB-2 / metabolism


16. Fiebrich H, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, van der Wal JE, Sluiter WJ, de Vries EG, Links TP: Sensitivity of 6-[F-18]fluoro-L-dihydroxyphenylalanine positron emission tomography for localizing tumors causing catecholamine excess. J Clin Oncol; 2009 May 20;27(15_suppl):11064

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity of 6-[F-18]fluoro-L-dihydroxyphenylalanine positron emission tomography for localizing tumors causing catecholamine excess.
  • : 11064 Background: Positron emission tomography (PET) using the catecholamine precursor 6-[F-18]fluoro-L-dihydroxyphenylalanine (<sup>18</sup>F-DOPA) has emerged as promising technique to localize tumors with catecholamine excess.
  • This study investigated the sensitivity of <sup>18</sup>F-DOPA PET, compared to <sup>123</sup>I-metaiodobenzylguanidine (<sup>123</sup>I-MIBG) scintigraphy and computer tomography (CT)/ magnetic resonance imaging (MRI) in patients with catecholamine excess.
  • METHODS: In a single center prospective study <sup>18</sup>F-DOPA PET was compared to <sup>123</sup>I-MIBG and CT/MRI in patients with catecholamine excess.
  • The tumor localization was found in 45 patients, 43 with <sup>18</sup>F-DOPA PET, 31 with <sup>123</sup>I-MIBG and 32 with CT/MRI, resulting with surgery in final diagnosis of pheochromocytoma in 40, adrenal hyperplasia in 2, paraganglioma in 2, ganglioneuroma in 1 and 3 unknown (as yet no lesion detected).
  • The <sup>8</sup>F-DOPA PET+CT/MRI combination was superior to <sup>123</sup>I-MIBG+CT/MRI (93 vs 76%, P<.001) Whole body metabolic burden measured with <sup>18</sup>F-DOPA PET correlated with plasma free normetanephrine (r=.82) and 24h urinary total normetanephrine (r=.84) and metanephrine (r=.57).
  • CONCLUSIONS: The sensitivity of <sup>18</sup>F-DOPA PET to localize tumors with catecholamine excess is superior to either <sup>123</sup>I-MIBG scintigraphy or CT/MRI.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963142.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Kamal AH, Swetz KM, Liu H, Ruegg SR, Carey EC, Whitford K, Bock FA, Creagan ET, Moynihan TJ, Kaur JS: Survival trends in palliative care patients with cancer: A Mayo Clinic 5-year review. J Clin Oncol; 2009 May 20;27(15_suppl):9592

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival trends in palliative care patients with cancer: A Mayo Clinic 5-year review.
  • : 9592 Background: Palliative care (PC) is an essential part of the continuum of care for cancer (CA) patients (pts).
  • Little is known about the aggregate characteristics and survival of pts receiving inpatient palliative care consultation (PCC).
  • METHODS: We reviewed data prospectively collected on patients seen by the Palliative Care Inpatient Consult Service at Mayo Clinic - Rochester from 2003-2008.
  • Cancer is the most common primary diagnosis (47%).
  • Growth in annual PCC has risen dramatically (113 in 2003 vs. 414 in 2007) despite stable total hospital admissions.
  • General medicine, medical cardiology, and medical intensive care unit services refer most often.
  • Most frequent issues addressed are goals of care, dismissal planning, and pain control (29%, 19%, 17%).
  • PCC in actively dying pts have increased with 27% of all non-operating room, non-trauma in-hospital deaths being seen.
  • Although CA pts have the highest median survival after PCC vs. other diagnoses (17 days, p = 0.018), we observed a five-year trend of decreasing survival from admission to death and PCC to death.
  • Median time from PCC to death is 33 versus 11.5 days (p<0.01).
  • Despite this, median hospital length of stay and time from PCC to discharge have remained fixed at 8 and 2.5 days, respectively.
  • With the trend of shorter survival after PCC, PC professionals have little over two days to implement a comprehensive, ongoing care plan.
  • This highlights the importance of earlier outpatient palliative care involvement with advanced cancer patients and families.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963727.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Extermann M: Geriatric oncology: The ultimate personalized cancer care. J Clin Oncol; 2009 May 20;27(15_suppl):s2a

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geriatric oncology: The ultimate personalized cancer care.
  • : s2a In many aspects, geriatric oncology is the quintessential expression of ASCO's 2009 theme: personalizing cancer care (PCC).
  • PCC has two aspects: the tumor and the patient.
  • Major efforts are conducted to identify mechanisms in an individual tumor that could be targeted more effectively by therapies.
  • As the world population ages, we are progressing toward providing cancer care tailored to both the tumor and the older cancer patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961889.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Robledo AB, Ponce Marco JL, Ibáñez TB, Meseguer Anastasio MF, Gómez-Gavara C: Pheochromocytomatosis: A Risk after Pheochromocytoma Surgery. Am Surg; 2010 Aug 01;76(8):122-124

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pheochromocytomatosis: A Risk after Pheochromocytoma Surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28958230.001).
  • [ISSN] 1555-9823
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. McCreadie SR, McGregory ME: Experiences incorporating Tablet PCcs into clinical pharmacists' workflow. J Healthc Inf Manag; 2005;19(4):32-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experiences incorporating Tablet PCcs into clinical pharmacists' workflow.
  • Tablet PCs are portable computers that combine the power of a laptop with an intuitive pendriven interface that have been heavily promoted for vertical industries such as healthcare.
  • The authors describe their experiences with tablet PCs used by clinical pharmacists in a large academic medical center.
  • Users reported increased efficiency on patient care rounds; they say they reduced or eliminated paper notes and shadow charts from their daily routine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266030.001).
  • [ISSN] 1099-811X
  • [Journal-full-title] Journal of healthcare information management : JHIM
  • [ISO-abbreviation] J Healthc Inf Manag
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kim YM, Kwak KH, Lim JO, Baek WY: Reduction of allodynia by intrathecal transplantation of microencapsulated porcine chromaffin cells. Artif Organs; 2009 Mar;33(3):240-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of allodynia by intrathecal transplantation of microencapsulated porcine chromaffin cells.
  • Bovine chromaffin cells (BCCs) are well known to have analgesic effect to reduce acute or chronic pain when transplanted in the subarachnoid space and have been considered as an alternative therapy for pain management.
  • In the present study, we investigated whether microencapsulated porcine adrenal medullary chromaffin cells (PCCs) also have analgesic effect to reduce allodynia caused by neuropathic pain in chronic constriction injury model of rat.
  • PCCs were isolated from a porcine adrenal medulla and then microencapsulated with alginate and poly.
  • In in vitro tests, the microencapsulated PCCs were investigated whether they have an ability to release catecholamines responding to nicotine stimulation.
  • The levels of catecholamines released from the microencapsulated PCCs were significantly higher than from microencapsulated BCCs.
  • In addition, the microencapsulated PCCs released catecholamines and met-enkephalin responding to cerebral spinal fluid (CSF) retrieved from a neuropathic pain model.
  • In in vivo tests, implantation of microencapsulated PCCs reduced both mechanical and cold allodynia in chronic constriction injury model of a rat whereas the microencapsulated BCCs reduced only cold allodynia under the same conditions.
  • The injection of antagonist of opioid peptides reversed the reduction of cold allodynia in microencapsulated PCC-received animal.
  • The levels of catecholamines in the CSF of rats after implantation of microencapsulated PCCs were significantly higher than in the control group.
  • These data suggest that microencapsulated PCCs may be another effective source for the treatment of neuropathic pain.
  • [MeSH-major] Cell- and Tissue-Based Therapy / methods. Chromaffin Cells / cytology. Chromaffin Cells / transplantation. Pain
  • [MeSH-minor] Animals. Behavior, Animal. Catecholamines / metabolism. Cattle. Cells, Cultured. Cerebrospinal Fluid / chemistry. Cerebrospinal Fluid / metabolism. Male. Models, Animal. Nicotine / metabolism. Polylysine / chemistry. Rats. Rats, Sprague-Dawley. Swine

  • MedlinePlus Health Information. consumer health - Pain.
  • Hazardous Substances Data Bank. NICOTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19245523.001).
  • [ISSN] 1525-1594
  • [Journal-full-title] Artificial organs
  • [ISO-abbreviation] Artif Organs
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Catecholamines; 25104-18-1 / Polylysine; 6M3C89ZY6R / Nicotine
  •  go-up   go-down


22. Sarvet B, Gold J, Bostic JQ, Masek BJ, Prince JB, Jeffers-Terry M, Moore CF, Molbert B, Straus JH: Improving access to mental health care for children: the Massachusetts Child Psychiatry Access Project. Pediatrics; 2010 Dec;126(6):1191-200
MedlinePlus Health Information. consumer health - Child Mental Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving access to mental health care for children: the Massachusetts Child Psychiatry Access Project.
  • BACKGROUND: Inadequate access to care for mentally ill children and their families is a persistent problem in the United States.
  • Although promotion of pediatric primary care clinicians (PCCs) in detection, management, and coordination of child mental health care is a strategy for improving access, limitations in training, time, and specialist availability represent substantial barriers.
  • The Massachusetts Child Psychiatry Access Project (MCPAP), publicly funded with 6 regional consultation teams, provides Massachusetts PCCs with rapid access to child psychiatry expertise, education, and referral assistance.
  • PCC surveys assessed satisfaction and impact on access to care.
  • RESULTS: The MCPAP enrolled 1341 PCCs in 353 practices covering 95% of the youth in Massachusetts.
  • PCCs contacted the MCPAP for diagnostic questions (34%), identifying community resources (27%), and consultation regarding medication (27%).
  • The rate of PCCs who reported that they are usually able to meet the needs of psychiatric patients increased from 8% to 63%.
  • Consultations were reported to be helpful by 91% of PCCs.
  • CONCLUSIONS: PCCs have used and value a statewide system that provides access to teams of psychiatric consultants.
  • Access to child mental health care may be substantially improved through public health interventions that promote collaboration between PCCs and child mental health specialists.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21059722.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Wonderlin WF: Constitutive, translation-independent opening of the protein-conducting channel in the endoplasmic reticulum. Pflugers Arch; 2009 Feb;457(4):917-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secretory and membrane proteins are translocated into the endoplasmic reticulum (ER) through a translocon assembled as a tetramer of Sec61 protein-conducting channels (PCC).
  • How the opening of the PCCs in the tetramer is regulated through the protein translocation cycle is poorly understood.
  • In this study, the permeability of PCCs in native ER membranes to small molecules was measured using fluorescence and electrophysiological techniques.
  • Although the PCCs were closed at 4 degrees C, they were constitutively open at physiological temperatures in the absence of protein translation or a bound ribosome.
  • The open PCCs occurred in clusters that are likely to correspond to the simultaneous opening of three or four PCCs in a translocon.
  • The binding of 60S subunits to a ribosome-free membrane increased the number of open PCCs but did not increase the single-channel conductance.
  • The translation-independent, constitutive opening of Sec61 PCCs provides new insight into the role of the translocon in the transport of small molecules across the ER membrane.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1973 Jan;56(1):206-29 [4682341.001]
  • [Cites] Methods Enzymol. 1983;96:84-93 [6656655.001]
  • [Cites] Cell. 2001 Nov 2;107(3):361-72 [11701126.001]
  • [Cites] Biochemistry. 1969 Mar;8(3):851-6 [4976408.001]
  • [Cites] Cell. 1996 Nov 15;87(4):721-32 [8929540.001]
  • [Cites] Biophys J. 1997 Jul;73(1):168-78 [9199781.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26479-85 [11994289.001]
  • [Cites] Biophys J. 2006 Apr 15;90(8):2718-30 [16461399.001]
  • [Cites] EMBO J. 2000 Apr 17;19(8):1900-6 [10775273.001]
  • [Cites] Cell. 1991 May 3;65(3):371-80 [1902142.001]
  • [Cites] J Mol Biol. 2002 Dec 6;324(4):871-86 [12460584.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Sep;291(3):C511-7 [16611737.001]
  • [Cites] Mol Cell. 2003 Jul;12 (1):261-8 [12887911.001]
  • [Cites] J Cell Biol. 2000 Jul 10;150(1):53-64 [10893256.001]
  • [Cites] Biochemistry. 2006 Oct 31;45(43):13018-24 [17059218.001]
  • [Cites] Cell. 1992 May 15;69(4):677-84 [1375130.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):663-9 [18046402.001]
  • [Cites] Pflugers Arch. 2007 Mar;453(6):797-808 [17171366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17404-9 [15585581.001]
  • [Cites] Mol Cell. 2007 May 25;26(4):511-21 [17531810.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):22655-62 [11303028.001]
  • [Cites] Mol Biol Cell. 2004 Feb;15(2):447-55 [14617815.001]
  • [Cites] Annu Rev Biochem. 1979;48:719-54 [382996.001]
  • [Cites] Cell. 2007 Apr 6;129(1):97-110 [17418789.001]
  • [Cites] J Biol Chem. 1981 Jun 25;256(12):6413-22 [7240215.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4397-403 [12458217.001]
  • [Cites] FASEB J. 1996 Feb;10(2):302-8 [8641563.001]
  • [Cites] J Biol Chem. 1990 Oct 5;265(28):17341-7 [2211627.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33820-7 [10931837.001]
  • [Cites] FEBS Lett. 1987 Nov 16;224(1):172-6 [2445602.001]
  • [Cites] Arch Biochem Biophys. 2007 Jun 1;462(1):115-21 [17481572.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Feb 27;219(3):916-22 [8645279.001]
  • [Cites] J Mol Biol. 1973 Mar 15;74(4):415-38 [4729519.001]
  • [Cites] Nature. 2004 Jan 1;427(6969):36-44 [14661030.001]
  • [Cites] J Gen Physiol. 1961 Jul;44:1189-99 [13748878.001]
  • [Cites] Biophys J. 2006 Apr 1;90(7):2356-67 [16415058.001]
  • [Cites] J Physiol. 1956 Apr 27;132(1):74-91 [13320373.001]
  • [Cites] Mol Cell. 2007 May 25;26(4):501-9 [17531809.001]
  • [Cites] Annu Rev Cell Dev Biol. 1999;15:799-842 [10611978.001]
  • [Cites] FASEB J. 2006 Jun;20(8):1215-7 [16611832.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(16):6176-80 [2474828.001]
  • [Cites] Mol Membr Biol. 2008 Feb;25(2):95-101 [18307097.001]
  • [Cites] Mol Biol Cell. 2006 Sep;17 (9):3860-9 [16822833.001]
  • [Cites] Cell. 1998 Mar 20;92(6):747-58 [9529251.001]
  • [Cites] EMBO J. 2005 Oct 5;24(19):3380-8 [16148946.001]
  • [Cites] Biophys J. 1994 Aug;67(2):590-602 [7524709.001]
  • [Cites] J Cell Biol. 1994 Aug;126(4):925-34 [8051212.001]
  • [Cites] J Mol Biol. 2005 Apr 29;348(2):445-57 [15811380.001]
  • [Cites] J Cell Biol. 2005 Apr 25;169(2):219-25 [15851514.001]
  • [Cites] FASEB J. 1995 Jun;9(9):788-98 [7601343.001]
  • (PMID = 18604553.001).
  • [ISSN] 0031-6768
  • [Journal-full-title] Pflugers Archiv : European journal of physiology
  • [ISO-abbreviation] Pflugers Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Protein Subunits; 0 / SEC Translocation Channels; 0 / SEC61 protein
  •  go-up   go-down


24. Federlin M, Hiller KA, Schmalz G: Controlled, prospective clinical split-mouth study of cast gold vs. ceramic partial crowns: 5.5 year results. Am J Dent; 2010 Jun;23(3):161-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To investigate the long-term clinical performance of cast gold partial crowns (CGPCs) as compared to partial ceramic crowns (PCCs).
  • The null hypothesis tested was that CGPCs and PCCs would show similar clinical outcomes.
  • In each patient, one CGPC (Degulor C) and one PCC (Vita Mark II ceramic/Cerec 3) had been inserted at baseline.
  • After 5.5 years, 22 CGPC and 22 PCC restorations in 22 subjects attending the recall visit were clinically assessed using modified United States Public Health Service (USPHS) criteria.
  • Kaplan-Meier survival rates were calculated for CGPCs and PCCs of the 29 subjects who had been originally enrolled in the study.
  • 22 CGPCs and 11 PCCs were placed in molars; 11 PCCs were placed in premolars.
  • After 5.5 years, PCCs revealed a statistically significant, time dependant decrease of Alfa ratings for criteria anatomic form, marginal adaptation and marginal discoloration.
  • Furthermore, PCCs as compared to CGPCs showed a statistically significant material-related decrease of Alfa ratings for criteria anatomic form and marginal discoloration.
  • Kaplan-Meier survival analysis revealed a 93.3% cumulative survival rate for CGPCs and an 88.8% cumulative survival rate for PCCs after 5.5 years.
  • At 5.5 years, CGPCs and PCCs exhibited satisfactory clinical outcomes.
  • For PCCs, Bravo ratings increased significantly over time, however this did not compromise clinical survival of the restorations as compared to CGPCs.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20718214.001).
  • [ISSN] 0894-8275
  • [Journal-full-title] American journal of dentistry
  • [ISO-abbreviation] Am J Dent
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gold Alloys; 12001-21-7 / Dental Porcelain
  •  go-up   go-down


25. Kupka S, Haack B, Zdichavsky M, Mlinar T, Kienzle C, Bock T, Kandolf R, Kroeber SM, Königsrainer A: Large proportion of low frequency microsatellite-instability and loss of heterozygosity in pheochromocytoma and endocrine tumors detected with an extended marker panel. J Cancer Res Clin Oncol; 2008 Apr;134(4):463-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large proportion of low frequency microsatellite-instability and loss of heterozygosity in pheochromocytoma and endocrine tumors detected with an extended marker panel.
  • PURPOSE: Pheochromocytoma (PCC) is a usually benign tumor originated in the majority of patients from the adrenal medulla.
  • Regarding sporadic forms of PCC, mechanisms of pathogenesis are largely unknown.
  • Recently, microsatellite-instability (MSI) was discussed as genetic factor contributing to PCC development.
  • Since microsatellite markers used for MSI detection have only been recommended for colorectal carcinoma (CRC), we established an extended marker set for MSI detection in PCC.
  • METHODS: Twenty-two PCC patients were analyzed applying 11 microsatellite markers.
  • RESULTS: Microsatellite-instability was detected in 41% of PCCs.
  • Among the 23 patients with endocrine tumors, only three (one pancreatic endocrine tumor, one duodenal neuro-endocrine tumor, one hepatic metastasis of a primary tumor with unknown origin) demonstrated MSI.
  • CONCLUSIONS: The extended microsatellite panel is qualified to detect MSI in PCC.
  • PCCs are characterized by low frequency MSI pointing to failures in factors involved in DNA replication.
  • [MeSH-major] Endocrine Gland Neoplasms / genetics. Loss of Heterozygosity. Microsatellite Instability. Microsatellite Repeats. Pheochromocytoma / genetics

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Teratog Carcinog Mutagen. 2003;Suppl 1:255-65 [12616616.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):241-9 [15944796.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):353-60 [11433399.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3444-9 [11705861.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):229-36 [15599934.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1564-7 [15619218.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):38-44 [8536886.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):285-92 [11196176.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(20):2347-54 [12351569.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):93-8 [17143284.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1114-5 [17021141.001]
  • [Cites] Hum Mol Genet. 1998 May;7(5):895-903 [9536095.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] In Vivo. 2005 Mar-Apr;19(2):359-65 [15796198.001]
  • [Cites] Hum Pathol. 2002 Mar;33(3):322-9 [11979373.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2536-40 [12171881.001]
  • [Cites] Int J Colorectal Dis. 2006 Oct;21(7):625-31 [16557375.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):10-1 [17192781.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):300-3 [9521327.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 15;150(2):128-35 [15066320.001]
  • [Cites] World J Surg. 2006 Jul;30(7):1240-6 [16715450.001]
  • [Cites] Exp Mol Med. 2004 Apr 30;36(2):122-9 [15150440.001]
  • [Cites] Breast Cancer Res Treat. 2000 Mar;60(2):135-42 [10845276.001]
  • [Cites] Surgery. 2003 Dec;134(6):902-8; discussion 909 [14668721.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Cancer Treat Rev. 2006 Dec;32(8):607-18 [17055172.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):145-52 [16724208.001]
  • (PMID = 17828419.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Levy JH, Tanaka KA, Dietrich W: Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology; 2008 Nov;109(5):918-26
Hazardous Substances Data Bank. WARFARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • European and American guidelines recommend prothrombin complex concentrates (PCCs) for anticoagulation reversal in patients with life-threatening bleeding and an increased international normalized ratio.
  • Compared with human fresh frozen plasma, PCCs provide quicker correction of the international normalized ratio and improved bleeding control.
  • Although there are historic concerns regarding potential infectious and thrombotic risks with PCCs, current PCC formulations are much improved.
  • Recombinant activated factor VII is a potential alternative to PCCs, but preclinical comparisons suggest that PCCs are more effective in correcting coagulopathy.
  • Although many patients who require rapid reversal of warfarin are currently treated with fresh frozen plasma, PCCs should be considered as an alternative therapy.
  • [MeSH-major] Hemostatics / therapeutic use. Perioperative Care / methods. Vitamin K / antagonists & inhibitors
  • [MeSH-minor] Blood Coagulation / drug effects. Blood Coagulation / physiology. Blood Coagulation Factors / pharmacology. Blood Coagulation Factors / therapeutic use. Blood Loss, Surgical / physiopathology. Blood Loss, Surgical / prevention & control. Disease Management. Humans. International Normalized Ratio / methods. Warfarin / adverse effects. Warfarin / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Vitamin K.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18946305.001).
  • [ISSN] 1528-1175
  • [Journal-full-title] Anesthesiology
  • [ISO-abbreviation] Anesthesiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Coagulation Factors; 0 / Hemostatics; 12001-79-5 / Vitamin K; 37224-63-8 / prothrombin complex concentrates; 5Q7ZVV76EI / Warfarin
  • [Number-of-references] 71
  •  go-up   go-down


27. Ceyhan GO, Demir IE, Altintas B, Rauch U, Thiel G, Müller MW, Giese NA, Friess H, Schäfer KH: Neural invasion in pancreatic cancer: a mutual tropism between neurons and cancer cells. Biochem Biophys Res Commun; 2008 Sep 26;374(3):442-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neural invasion by pancreatic cancer cells (PCC) worsens the prognosis and frequently limits curative resection.
  • We established a novel in-vitro model in which T3M4-PCCs were co-cultured with either isolated myenteric plexus cells (MP) or dorsal root ganglia (DRG) of newborn rats within a three-dimensional extracellular matrix gel.
  • The close vicinity of MP or DRG to T3M4-PCCs induced early morphologic changes on T3M4-PCCs at the migration front prior to the migration process with elongated and neurite-targeting PCCs, compared to round and non-grouping at the non-migrating front.
  • T3M4-PCCs built cancer-cell clusters around the DRG or MP, a process which was accelerated by increasing number of T3M4-PCCs or neurons.
  • These findings indicate that neuro-cancer interactions start prior to PCC migration and induce evident changes in cancer and nerve biology.
  • These findings can be reproduced within the introduced 3D in-vitro migration assay which allows investigation in the early pathogenesis of neural PCC invasion.
  • [MeSH-minor] Animals. Cell Line, Tumor. Coculture Techniques. Ganglia, Spinal / pathology. Glial Cell Line-Derived Neurotrophic Factor. Humans. Myenteric Plexus / pathology. Neoplasm Invasiveness. Nerve Growth Factor / pharmacology. Rats. Rats, Sprague-Dawley. Tropism

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18640096.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Cell Line-Derived Neurotrophic Factor; 9061-61-4 / Nerve Growth Factor
  •  go-up   go-down


28. De Krijger RR, Petri BJ, Van Nederveen FH, Korpershoek E, De Herder WW, De Muinck Keizer-Schrama SM, Dinjens WN: Frequent genetic changes in childhood pheochromocytomas. Ann N Y Acad Sci; 2006 Aug;1073:166-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent genetic changes in childhood pheochromocytomas.
  • Pheochromocytomas (PCCs) are rare catecholamine-producing tumors of the adrenal gland which may also occur elsewhere in the abdomen and are then called paragangliomas.
  • A proportion of PCCs occurs in hereditary cancer syndromes, including multiple endocrine neoplasia Type 2 (MEN2), caused by mutations in the RET proto-oncogene, von Hippel-Lindau (VHL) disease, caused by VHL gene abnormalities, and the pheochromocytoma-paraganglioma (PCC-PGL) syndrome, caused by mutations in SDHB and SDHD.
  • Since a proportion of PCCs occurs in children we hypothesized that germline mutations in RET, VHL, succinate dehydrogenase subunit B (SDHB), and subunit D (SDHD) occur more frequently in the pediatric age range.
  • From our single-institution collection of PCCs, we have selected 10 cases that occurred in individuals up to 18 years of age at diagnosis.
  • In these, we have performed mutation analysis on normal and tumor tissues for exons 10, 11, and 16 of RET and for the entire coding sequence of VHL, SDHB, and SDHD.
  • In the remaining 7 patients there was one patient from a family fulfilling the clinical criteria for VHL disease.
  • All tumors were benign (average follow-up: 12 years) and were located in the adrenal.
  • From our findings we conclude that (a) a large proportion (40%) of pediatric PCC patients is diagnosed in the context of inherited cancer syndromes, and (b) candidate gene analysis appears to be indicated to detect germline mutations.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Pheochromocytoma / genetics
  • [MeSH-minor] Base Sequence. Child. DNA Primers. Electrophoresis, Polyacrylamide Gel. Genetic Predisposition to Disease. Humans. Polymorphism, Single-Stranded Conformational. Proto-Oncogene Proteins c-ret / genetics. Succinate Dehydrogenase / genetics. Von Hippel-Lindau Tumor Suppressor Protein / genetics

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann N Y Acad Sci. 2006;1086:241. Petri, Bart-Jeroen [added]
  • (PMID = 17102083.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 1.3.99.1 / Succinate Dehydrogenase; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  •  go-up   go-down


29. Suh KY, Lacouture M, Gerami P: p63 in Primary Cutaneous Carcinosarcoma. Am J Dermatopathol; 2007 Aug;29(4):374-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 in Primary Cutaneous Carcinosarcoma.
  • Primary cutaneous carcinosarcomas (PCCs) are rare malignant neoplasms that are characterized by biphasic epithelial and mesenchymal differentiation.
  • When the biphasic nature is not evident, immunohistochemical studies may be important in the diagnosis of PCCs.
  • We report 3 cases of PCC.
  • The clearly epithelial areas of each tumor were frequently positive for both markers, whereas the sarcomatous areas were negative for both markers.
  • These 3 cases suggest that the use of both p63 and routine cytokeratin markers such as AE1/AE3 can increase the sensitivity for distinguishing epithelial cells over a range of differentiation states, which we propose will aid in the diagnosis of PCCs.
  • In addition, the staining pattern of AE1/AE3 and p63 in these cases further supports the conversion theory of PCC.
  • [MeSH-major] Carcinosarcoma / pathology. DNA-Binding Proteins / analysis. Skin Neoplasms / pathology. Trans-Activators / analysis. Tumor Suppressor Proteins / analysis
  • [MeSH-minor] Aged. Aged, 80 and over. Anion Exchange Protein 1, Erythrocyte / analysis. Antiporters / analysis. Biomarkers, Tumor / analysis. Cell Differentiation. Epithelial Cells / pathology. Humans. Keratins / analysis. Male. Middle Aged. Transcription Factors. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667171.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anion Exchange Protein 1, Erythrocyte; 0 / Antiporters; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / SLC4A3 protein, human; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


30. Holtman CK, Chen Y, Sandoval P, Gonzales A, Nalty MS, Thomas TL, Youderian P, Golden SS: High-throughput functional analysis of the Synechococcus elongatus PCC 7942 genome. DNA Res; 2005;12(2):103-15
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-throughput functional analysis of the Synechococcus elongatus PCC 7942 genome.
  • Synechococcus elongatus PCC 7942 was the first cyanobacterial strain to be reliably transformed by exogenously added DNA and has become the model organism for cyanobacterial circadian rhythms.
  • With a small genome (2.7 Mb) and well-developed genetic tools, PCC 7942 provides an exceptional opportunity to elucidate the circadian mechanism through genetics.
  • Cosmid clones that carry inserts of PCC 7942 DNA are saturated with transposon insertions in vitro to provide sequencing templates and substrates for mutagenesis of the PCC 7942 genome via homologous recombination.
  • PCC 7942 mutants defective for 490 different genes have been screened for circadian phenotypes.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16303742.001).
  • [ISSN] 1756-1663
  • [Journal-full-title] DNA research : an international journal for rapid publication of reports on genes and genomes
  • [ISO-abbreviation] DNA Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS39546; United States / NIGMS NIH HHS / GM / R01 GM59336
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Japan
  •  go-up   go-down


31. Schenke F, Federlin M, Hiller KA, Moder D, Schmalz G: Controlled, prospective, randomized, clinical evaluation of partial ceramic crowns inserted with RelyX Unicem with or without selective enamel etching. 1-year results. Am J Dent; 2010 Oct;23(5):240-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To compare the performance of partial ceramic crowns (PCCs) inserted with RelyX Unicem (RXU) either with (RXU+E) or without (RXU) selective enamel etching.
  • METHODS: 34 patients (15 male, 19 female) participated in the investigation, with a total of 68 PCC restorations.
  • In each patient, one PCC was randomly assigned to insertion with RXU, the second PCC was assigned to insertion with RXU+E.
  • The PCCs were CAD/CAM fabricated using the Cerec 3 system.
  • RXU: 25 PCCs were placed in molars, nine in premolars.
  • RXU+E: 26 PCCs were placed in molars, eight in premolars.
  • One PCC (RXU) debonded after 11 months in situ, one PCC (RXU+E) fractured after 12 months in situ.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21207788.001).
  • [ISSN] 0894-8275
  • [Journal-full-title] American journal of dentistry
  • [ISO-abbreviation] Am J Dent
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Rely X Unicem; 0 / Resin Cements; 12001-21-7 / Dental Porcelain
  •  go-up   go-down


32. López-Jiménez E, Gómez-López G, Leandro-García LJ, Muñoz I, Schiavi F, Montero-Conde C, de Cubas AA, Ramires R, Landa I, Leskelä S, Maliszewska A, Inglada-Pérez L, de la Vega L, Rodríguez-Antona C, Letón R, Bernal C, de Campos JM, Diez-Tascón C, Fraga MF, Boullosa C, Pisano DG, Opocher G, Robledo M, Cascón A: Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol; 2010 Dec;24(12):2382-91
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas.
  • The six major genes involved in hereditary susceptibility for pheochromocytoma (PCC)/paraganglioma (PGL) (RET, VHL, NF1, SDHB, SDHC, and SDHD) have been recently integrated into the same neuronal apoptotic pathway where mutations in any of these genes lead to cell death.
  • The aim of the study was to decipher specific alterations associated with the different genetic classes of PCCs/PGLs.
  • Nevertheless, when we compared VHL tumors with SDHB cases, which often exhibit a malignant behavior, we found that HIF-1α target genes showed a predominant activation in the VHL PCCs.
  • These findings pave the way for more specific therapeutic approaches for malignant PCCs/PGLs management based on the patient's genetic alteration.
  • [MeSH-major] Cell Death / genetics. Paraganglioma / genetics. Pheochromocytoma / genetics. Succinate Dehydrogenase / genetics. Von Hippel-Lindau Tumor Suppressor Protein / genetics
  • [MeSH-minor] Adolescent. Adrenal Gland Neoplasms / genetics. Adrenal Gland Neoplasms / metabolism. Adult. Aged. Basic Helix-Loop-Helix Transcription Factors / genetics. Basic Helix-Loop-Helix Transcription Factors / metabolism. Child. Dioxygenases / genetics. Dioxygenases / metabolism. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / genetics. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Hypoxia-Inducible Factor-Proline Dioxygenases. Middle Aged. Neoplasms / genetics. Young Adult. von Hippel-Lindau Disease / genetics. von Hippel-Lindau Disease / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Cancer Cell. 2009 Sep 8;16(3):180-2 [19732718.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Nat Genet. 2010 Mar;42(3):229-33 [20154675.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4734-44 [12879018.001]
  • [Cites] PLoS Genet. 2005 Jul;1(1):72-80 [16103922.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):155-67 [16098468.001]
  • [Cites] Nat Rev Cancer. 2008 Nov;8(11):865-73 [18923434.001]
  • [Cites] Dev Cell. 2005 Nov;9(5):617-28 [16256737.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12 ):9519-25 [11120745.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6916-23 [18980986.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):897-911 [15613462.001]
  • [Cites] J Biol Chem. 2010 Mar 19;285(12 ):8927-35 [20089853.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4593-8 [16954163.001]
  • [Cites] Science. 2009 Aug 28;325(5944):1139-42 [19628817.001]
  • [Cites] Gastroenterology. 2010 Feb;138(2):606-15 [19786027.001]
  • [Cites] Horm Metab Res. 2009 Sep;41(9):687-96 [19672813.001]
  • [Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W486-91 [16845056.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5615-21 [14500403.001]
  • [Cites] Mol Cell Biol. 2007 Sep;27(17 ):6229-42 [17576813.001]
  • [Cites] PLoS One. 2009 Sep 18;4(9):e7094 [19763184.001]
  • [Cites] Oncogene. 2009 Apr 9;28(14 ):1694-705 [19252526.001]
  • [Cites] Genes Dev. 2008 Apr 1;22(7):884-93 [18334619.001]
  • [Cites] Bioinformatics. 2005 May 1;21(9):2067-75 [15657102.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4366-71 [10969779.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4505-9 [16912137.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):597-609 [15607964.001]
  • [Cites] Bioinformatics. 2007 Oct 15;23(20):2700-7 [17720982.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4058-67 [18519664.001]
  • [Cites] Nucleic Acids Res. 2009 Jul;37(Web Server issue):W581-6 [19435879.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9190-3 [16230378.001]
  • [Cites] Bioinformatics. 2004 Jul 22;20(11):1797-8 [14988123.001]
  • [Cites] Behav Brain Res. 2001 Nov 1;125(1-2):279-84 [11682119.001]
  • [Cites] EMBO J. 2003 Aug 15;22(16):4082-90 [12912907.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(13):5675-86 [15964822.001]
  • [Cites] Am J Pathol. 2010 Jul;177(1):84-96 [20522651.001]
  • [Cites] J Cell Biochem. 2004 Jun 1;92 (3):491-501 [15156561.001]
  • [Cites] Hum Mol Genet. 2010 Aug 1;19(15):3011-20 [20484225.001]
  • [Cites] Eur J Haematol. 2010 Jan 1;84(1):47-51 [19737309.001]
  • [Cites] Nucleic Acids Res. 2009 Aug;37(14):4587-602 [19491311.001]
  • [Cites] J Biol Chem. 2007 Apr 27;282(17 ):12410-8 [17344222.001]
  • (PMID = 20980436.001).
  • [ISSN] 1944-9917
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / endothelial PAS domain-containing protein 1; EC 1.13.11.- / Dioxygenases; EC 1.14.11.29 / EGLN3 protein, human; EC 1.14.11.29 / Hypoxia-Inducible Factor-Proline Dioxygenases; EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase; EC 2.3.2.27 / Von Hippel-Lindau Tumor Suppressor Protein; EC 6.3.2.- / VHL protein, human
  •  go-up   go-down


33. Kang SS, Conway PL: Characteristics of the adhesion of PCC Lactobacillus fermentum VRI 003 to Peyer's patches. FEMS Microbiol Lett; 2006 Aug;261(1):19-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of the adhesion of PCC Lactobacillus fermentum VRI 003 to Peyer's patches.
  • The characteristics of the adhesion of PCC Lactobacillus fermentum VRI 003 to Peyer's patches was studied in vitro.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16842353.001).
  • [ISSN] 0378-1097
  • [Journal-full-title] FEMS microbiology letters
  • [ISO-abbreviation] FEMS Microbiol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carbohydrates; 0 / Membrane Proteins; 0 / Methylmannosides; 51023-63-3 / methylmannoside; EC 3.4.21.64 / Endopeptidase K; PHA4727WTP / Mannose
  •  go-up   go-down


34. Oishi Y, Nagai S, Yoshida M, Fujisawa S, Sazawa A, Shinohara N, Nonomura K, Matsuno K, Shimizu C: Mutation analysis of the SDHB and SDHD genes in pheochromocytomas and paragangliomas: identification of a novel nonsense mutation (Q168X) in the SDHB gene. Endocr J; 2010;57(8):745-50
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation analysis of the SDHB and SDHD genes in pheochromocytomas and paragangliomas: identification of a novel nonsense mutation (Q168X) in the SDHB gene.
  • Pheochromocytoma (PCC) and paraganglioma (PGL) are tumors of the autonomic nervous system.
  • The former is a tumor that occurs in only adrenal glands, and the latter can be found in the head and neck or in the thorax and abdomen.
  • In PCC and PGL, genetic mutations account for approximately 30% of functional (secrete catecholamines) and nonfunctional cases.
  • In addition to RET, VHL and NF-1, genes encoding succinate dehydrogenase complex subunit B (SDHB), subunit C (SDHC), and subunit D (SDHD) are recognized as susceptibility genes for PCC and PGL.
  • Recently, PCC and PGL caused by genetic mutations of SDHB, SDHC and SDHD were established as hereditary pheochromocytoma paraganglioma syndrome (HPPS).
  • Approximately 15% of all PCCs and PGLs are recognized as HPPS.
  • The aim of this study was to analyze SDHB and SDHD mutations in PCC and PGL patients.
  • A number of studies have reported that SDHB mutation-associated disease demonstrates a higher rate of malignancy.
  • [MeSH-major] Codon, Nonsense. Paraganglioma / genetics. Pheochromocytoma / genetics. Succinate Dehydrogenase / genetics
  • [MeSH-minor] Adolescent. Adrenal Gland Neoplasms / genetics. Adult. Aged. DNA Mutational Analysis. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Single Nucleotide. Sequence Analysis, DNA

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505258.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / SDHD protein, human; EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase
  •  go-up   go-down


35. Liu X, Curtiss R 3rd: Nickel-inducible lysis system in Synechocystis sp. PCC 6803. Proc Natl Acad Sci U S A; 2009 Dec 22;106(51):21550-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nickel-inducible lysis system in Synechocystis sp. PCC 6803.
  • PCC 6803 to facilitate extracting lipids for biofuel production.
  • Several bacteriophage-derived lysis genes were integrated into the genome and placed downstream of a nickel-inducible signal transduction system.
  • PCC 6803 cells with this system by the addition of NiSO(4).

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • Hazardous Substances Data Bank. NICKEL SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bacteriol. 2000 Mar;182(5):1191-9 [10671437.001]
  • [Cites] Mol Microbiol. 2008 Oct;70(2):341-51 [18713319.001]
  • [Cites] Trends Microbiol. 2000 Mar;8(3):120-8 [10707065.001]
  • [Cites] Anal Biochem. 2000 Sep 10;284(2):388-93 [10964424.001]
  • [Cites] Annu Rev Microbiol. 2000;54:799-825 [11018145.001]
  • [Cites] J Bacteriol. 2002 Jan;184(1):307-12 [11741872.001]
  • [Cites] FEMS Microbiol Lett. 2002 Jan 10;206(2):215-9 [11814666.001]
  • [Cites] Mol Microbiol. 2002 Jan;43(1):247-56 [11849552.001]
  • [Cites] Adv Biochem Eng Biotechnol. 2004;90:113-33 [15453187.001]
  • [Cites] Eur J Biochem. 1979 Jun 1;96(3):581-4 [380988.001]
  • [Cites] Can J Microbiol. 1980 Feb;26(2):204-8 [6773644.001]
  • [Cites] FEMS Microbiol Rev. 1995 Aug;17(1-2):191-205 [7669346.001]
  • [Cites] Gene. 1997 Feb 20;186(1):29-35 [9047341.001]
  • [Cites] Appl Environ Microbiol. 1997 Jun;63(6):2421-31 [9172364.001]
  • [Cites] Nat Biotechnol. 1997 Oct;15(10):976-9 [9335048.001]
  • [Cites] Curr Opin Microbiol. 2005 Aug;8(4):480-7 [15979390.001]
  • [Cites] Appl Environ Microbiol. 2005 Oct;71(10):5678-84 [16204475.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35433-9 [16103125.001]
  • [Cites] Arch Microbiol. 2006 Jan;184(5):259-70 [16320037.001]
  • [Cites] Genetics. 2006 Jan;172(1):17-26 [16219778.001]
  • [Cites] FEMS Microbiol Lett. 2006 Mar;256(1):159-64 [16487334.001]
  • [Cites] FEMS Microbiol Lett. 2006 Dec;265(1):133-9 [17054440.001]
  • [Cites] Arch Microbiol. 2007 Apr;187(4):265-79 [17160677.001]
  • [Cites] Virology. 2007 Sep 15;366(1):28-39 [17499329.001]
  • [Cites] Chem Rec. 2008;8(2):67-74 [18366103.001]
  • [Cites] Biotechnol Bioeng. 2008 Jun 1;100(2):203-12 [18431744.001]
  • [Cites] Biotechnol Bioeng. 2008 Aug 1;100(5):902-10 [18383143.001]
  • [Cites] Curr Opin Biotechnol. 2008 Jun;19(3):235-40 [18539450.001]
  • [Cites] J Bacteriol. 2000 Mar;182(6):1507-14 [10692354.001]
  • (PMID = 19995962.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biofuels; 4FLT4T3WUN / nickel sulfate; 7OV03QG267 / Nickel
  • [Other-IDs] NLM/ PMC2799798
  •  go-up   go-down


36. Zhang HY, Wang SJ, Xing J, Liu B, Ma ZL, Yang M, Zhang ZJ, Teng GJ: Detection of PCC functional connectivity characteristics in resting-state fMRI in mild Alzheimer's disease. Behav Brain Res; 2009 Jan 30;197(1):103-8
SciCrunch. NeuroSynth: Data: Activation Foci .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of PCC functional connectivity characteristics in resting-state fMRI in mild Alzheimer's disease.
  • Resting-state networks dissociate in the early stage of Alzheimer's disease (AD).
  • The posterior cingulate cortex (PCC) in AD brain is vulnerable to isolation from the rest of brain.
  • However, it remains unclear how this functional connectivity is related to PCC changes.
  • We employed resting-state functional MRI (fMRI) to examine brain regions with a functional connection to PCC in a mild AD group compared with matched control subjects.
  • PCC connectivity was gathered by investigating synchronic low frequency fMRI signal fluctuations with a temporal correlation method.
  • We found asymmetric PCC-left hippocampus, right dorsal-lateral prefrontal cortex and right thalamus connectivity disruption.
  • In addition, some other regions such as the bilateral visual cortex, the infero-temporal cortex, the posterior orbital frontal cortex, the ventral medial prefrontal cortex and the precuneus showed decreased functional connectivity to the PCC.
  • These regions included the medial prefrontal cortex, bilateral dorsal-lateral prefrontal cortex, the left basal ganglia and the left primary motor cortex.
  • [MeSH-major] Alzheimer Disease / physiopathology. Brain Mapping. Gyrus Cinguli / physiology. Nerve Net / physiology. Neural Pathways / physiology. Rest / physiology

  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18786570.001).
  • [ISSN] 1872-7549
  • [Journal-full-title] Behavioural brain research
  • [ISO-abbreviation] Behav. Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


37. Dargaud Y, Desmurs-Clavel H, Marin S, Bordet JC, Poplavsky JL, Negrier C: Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study. J Thromb Haemost; 2008 Jun;6(6):962-8
MedlinePlus Health Information. consumer health - Blood Thinners.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the capacities of two prothrombin complex concentrates to restore thrombin generation in plasma from orally anticoagulated patients: an in vitro study.
  • BACKGROUND: Human prothrombin complex concentrates (PCCs) are used for prevention and treatment of bleeding episodes in patients under warfarin therapy.
  • PCCs contain human factor (F) II, FVII, FIX, FX, protein C and protein S.
  • The concentrations of these coagulation factors contained in PCCs are variable and do not reflect entirely the capacity of these drugs to correct hemostasis.
  • Furthermore, commercially available PCCs do not have exactly the same composition, though they are all labelled and prescribed in units per kg of FIX (10-40 IU of FIX/kg).
  • As the final product generated by PCCs is thrombin, a thrombin generation (TG) test could theoretically be used for monitoring the hemostatic correction.
  • METHODS: TG was measured in platelet free plasma in the presence of tissue factor 5 pm and phospholipids 4 microM with a final concentration of PCC of 0-0.1-0.2-0.3-0.4-0.5-0.75-1 IU ml(-1).
  • FII, FVII, FIX, FX, protein C and protein S) were determined for each concentration of two different PCCs available on the French market.
  • RESULTS AND DISCUSSION: Our results showed that the addition of two different PCCs dose-dependently increased the TG capacity in patients with INR of 2-2.5-3-4 and >7 (n = 15 subjects) that reached the normal values.
  • The two PCCs improved the TG parameters differently with increasing concentrations.
  • These results strongly suggest that TG assay could be used for monitoring the clinical efficacy of PCC and for optimizing the therapeutic regimen towards a more individualized therapy involving the type of the bleeding complications, the level of inhibition of the coagulation system and the molecule content of the PCC.

  • Genetic Alliance. consumer health - Prothrombin.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373620.001).
  • [ISSN] 1538-7836
  • [Journal-full-title] Journal of thrombosis and haemostasis : JTH
  • [ISO-abbreviation] J. Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Blood Coagulation Factors; 0 / Enzyme Precursors; 0 / Protein C; 12001-79-5 / Vitamin K; 37224-63-8 / prothrombin complex concentrates; EC 3.4.21.5 / Thrombin
  •  go-up   go-down


38. Chowdary P, Nair D, Davies N, Malde R, Gatt A: Anaphylactic reaction with prothrombin complex concentrate in a patient with IgA deficiency and anti-IgA antibodies. Blood Coagul Fibrinolysis; 2010 Dec;21(8):764-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaphylactic reaction with prothrombin complex concentrate in a patient with IgA deficiency and anti-IgA antibodies.
  • Immunoglobulin A (IgA) deficiency with anti-IgA antibodies is not listed as an absolute or relative contraindication for the use of prothrombin complex concentrates (PCCs).
  • We discuss a patient who developed an anaphylactic reaction to PCC on a background of selective IgA deficiency with anti-IgA antibodies and with a history of anaphylactic reaction to other blood products.
  • Further analysis of PCCs revealed the presence of variable quantities of immunoglobulins of all classes, including IgA.
  • Although the summary of product characteristics for PCCs from various manufacturers does not list IgA deficiency with anti-IgA antibodies as an absolute or relative contraindication, our findings suggest that PCCs are not devoid of IgA and great caution must be exercised with their use in patients with IgA deficiency with anti-IgA antibodies and with previously documented reactions.

  • Genetic Alliance. consumer health - Prothrombin.
  • MedlinePlus Health Information. consumer health - Anaphylaxis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20885296.001).
  • [ISSN] 1473-5733
  • [Journal-full-title] Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • [ISO-abbreviation] Blood Coagul. Fibrinolysis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Blood Coagulation Factors; 0 / anti-IgA; 37224-63-8 / prothrombin complex concentrates
  •  go-up   go-down


39. Janssen PJ, Morin N, Mergeay M, Leroy B, Wattiez R, Vallaeys T, Waleron K, Waleron M, Wilmotte A, Quillardet P, de Marsac NT, Talla E, Zhang CC, Leys N: Genome sequence of the edible cyanobacterium Arthrospira sp. PCC 8005. J Bacteriol; 2010 May;192(9):2465-6
StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome sequence of the edible cyanobacterium Arthrospira sp. PCC 8005.
  • PCC 8005, a cyanobacterial strain of great interest to the European Space Agency for its nutritive value and oxygenic properties in the Micro-Ecological Life Support System Alternative (MELiSSA) biological life support system for long-term manned missions into space.

  • REBASE - The Restriction Enzyme Database. gene/protein/disease-specific - REBASE ref# 11652 .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2006;34(1):53-65 [16407324.001]
  • [Cites] Appl Environ Microbiol. 2008 Oct;74(19):6102-13 [18676712.001]
  • [Cites] Res Microbiol. 2006 Jan-Feb;157(1):77-86 [16431089.001]
  • (PMID = 20233937.001).
  • [ISSN] 1098-5530
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ ADDH01000000
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2863490
  •  go-up   go-down


40. Nakasugi K, Alexova R, Svenson CJ, Neilan BA: Functional analysis of PilT from the toxic cyanobacterium Microcystis aeruginosa PCC 7806. J Bacteriol; 2007 Mar;189(5):1689-97
StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional analysis of PilT from the toxic cyanobacterium Microcystis aeruginosa PCC 7806.
  • Since the microcystin-producing Microcystis aeruginosa PCC 7806 is naturally transformable, we have initiated the characterization of its type IV pilus system, involved in DNA uptake in many bacteria, to provide a physiological focus for the influence of gene transfer in microcystin evolution.
  • The type IV pilus genes pilA, pilB, pilC, and pilT were shown to be expressed in M. aeruginosa PCC 7806.
  • Heterologous expression indicated that it could complement the pilT mutant of Pseudomonas aeruginosa, but not that of the cyanobacterium Synechocystis sp. strain PCC 6803, which was unexpected.
  • Differences in two critical residues between the M. aeruginosa PCC 7806 PilT (7806 PilT) and the Synechocystis sp. strain PCC 6803 PilT proteins affected their theoretical structural models, which may explain the nonfunctionality of 7806 PilT in its cyanobacterial counterpart.

  • COS Scholar Universe. author profiles.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene. 1994 Oct 11;148(1):81-6 [7926843.001]
  • [Cites] Nature. 2000 Sep 7;407(6800):98-102 [10993081.001]
  • [Cites] Biochemistry. 1995 Jan 10;34(1):273-7 [7819207.001]
  • [Cites] Mol Microbiol. 1995 May;16(3):485-96 [7565109.001]
  • [Cites] Appl Environ Microbiol. 1995 Nov;61(11):3875-83 [8526499.001]
  • [Cites] FEMS Microbiol Lett. 1996 Nov 15;145(1):107-11 [8931334.001]
  • [Cites] Gene. 1996 Nov 7;179(1):147-55 [8955641.001]
  • [Cites] Gene. 1997 Jun 11;192(1):125-34 [9224882.001]
  • [Cites] Mol Microbiol. 1997 Nov;26(4):779-87 [9427407.001]
  • [Cites] Electrophoresis. 1997 Dec;18(15):2714-23 [9504803.001]
  • [Cites] Mol Microbiol. 1999 Apr;32(1):1-10 [10216854.001]
  • [Cites] J Bacteriol. 1999 Jul;181(13):4089-97 [10383979.001]
  • [Cites] Appl Environ Microbiol. 2004 Nov;70(11):6353-62 [15528492.001]
  • [Cites] J Bacteriol. 2005 Jan;187(1):249-56 [15601709.001]
  • [Cites] J Bacteriol. 2005 Feb;187(3):829-39 [15659660.001]
  • [Cites] J Bacteriol. 2005 Feb;187(4):1455-64 [15687210.001]
  • [Cites] Mol Microbiol. 2005 Aug;57(4):878-88 [16091031.001]
  • [Cites] Appl Environ Microbiol. 2005 Nov;71(11):7621-5 [16269818.001]
  • [Cites] Annu Rev Microbiol. 1999;53:217-44 [10547691.001]
  • [Cites] J Bacteriol. 2000 Apr;182(8):2184-90 [10735861.001]
  • [Cites] Chem Biol. 2000 Oct;7(10):753-64 [11033079.001]
  • [Cites] J Appl Microbiol. 2000 Dec;89(6):979-91 [11123471.001]
  • [Cites] Plant Cell Physiol. 2001 Jan;42(1):63-73 [11158445.001]
  • [Cites] Appl Environ Microbiol. 2001 Jun;67(6):2810-8 [11375198.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6901-4 [11381130.001]
  • [Cites] J Bacteriol. 2001 Aug;183(16):4694-701 [11466271.001]
  • [Cites] DNA Res. 2001 Oct 31;8(5):205-13; 227-53 [11759840.001]
  • [Cites] Curr Biol. 2002 Apr 16;12(8):R297-303 [11967173.001]
  • [Cites] Annu Rev Microbiol. 2002;56:289-314 [12142488.001]
  • [Cites] Plant Cell Physiol. 2002 Oct;43(10):1127-36 [12407192.001]
  • [Cites] Mol Microbiol. 2002 Nov;46(3):749-60 [12410832.001]
  • [Cites] J Bacteriol. 2002 Dec;184(23):6465-71 [12426333.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16012-7 [12446837.001]
  • [Cites] J Bacteriol. 2003 Jan;185(2):564-72 [12511503.001]
  • [Cites] J Bacteriol. 2003 May;185(9):2774-85 [12700256.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3381-5 [12824332.001]
  • [Cites] Nature. 2003 Aug 28;424(6952):1037-42 [12917641.001]
  • [Cites] J Mol Biol. 2003 Oct 24;333(3):657-74 [14556751.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):568-73 [14701903.001]
  • [Cites] Appl Environ Microbiol. 2004 Feb;70(2):686-92 [14766543.001]
  • [Cites] Anal Biochem. 1979 Nov 15;100(1):95-7 [161695.001]
  • [Cites] EMBO J. 1982;1(8):945-51 [6329717.001]
  • [Cites] Anal Biochem. 1986 Sep;157(2):375-80 [2946250.001]
  • [Cites] Gene. 1991 May 15;101(1):33-44 [1676385.001]
  • [Cites] J Bacteriol. 1993 Mar;175(6):1806-13 [8449886.001]
  • [Cites] Mol Microbiol. 1994 Apr;12(2):287-99 [8057853.001]
  • [Cites] Microbiology. 2006 Dec;152(Pt 12):3623-31 [17159215.001]
  • [Cites] Mol Microbiol. 2000 Aug;37(4):941-51 [10972813.001]
  • [Cites] Microbiol Rev. 1994 Sep;58(3):563-602 [7968924.001]
  • (PMID = 17172325.001).
  • [ISSN] 0021-9193
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ666165/ DQ666166/ DQ666168/ DQ666169/ EF051581/ EF051582/ EF058234
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Molecular Motor Proteins; EC 3.6.1.- / Adenosine Triphosphatases
  • [Other-IDs] NLM/ PMC1855755
  •  go-up   go-down


41. Claesson C, Hällgren A, Nilsson M, Svensson E, Hanberger H, Nilsson LE, Scope Study Group: Susceptibility of staphylococci and enterococci to antimicrobial agents at different ward levels in four north European countries. Scand J Infect Dis; 2007;39(11-12):1002-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A multicentre susceptibility study was performed on staphylococci and enterococci isolated from patients at 3 different ward levels: primary care centres (PCCs), general hospital wards (GHWs) and intensive care units (ICUs), in Denmark, Finland, Norway and Sweden.
  • There was a markedly higher incidence of resistance among CoNS in ICUs compared to GHWs and PCCs.
  • The prevalence of E. faecium isolates in this study differed significantly between the ward levels with the lowest prevalence found at PCCs.
  • The HLGR rate was significantly higher among E. faecalis from hospitalized patients (GHWs and ICUs) compared to patients at PCCs.

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852944.001).
  • [ISSN] 0036-5548
  • [Journal-full-title] Scandinavian journal of infectious diseases
  • [ISO-abbreviation] Scand. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


42. Koyama K, Tsuchiya T, Akimoto S, Yokono M, Miyashita H, Mimuro M: New linker proteins in phycobilisomes isolated from the cyanobacterium Gloeobacter violaceus PCC 7421. FEBS Lett; 2006 Jun 12;580(14):3457-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New linker proteins in phycobilisomes isolated from the cyanobacterium Gloeobacter violaceus PCC 7421.
  • Two new linker proteins were identified by peptide mass fingerprinting in phycobilisomes isolated from the cyanobacterium Gloeobacter violaceus PCC 7421.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16714023.001).
  • [ISSN] 0014-5793
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Phycobilisomes
  •  go-up   go-down


43. Baran R, Bowen BP, Bouskill NJ, Brodie EL, Yannone SM, Northen TR: Metabolite identification in Synechococcus sp. PCC 7002 using untargeted stable isotope assisted metabolite profiling. Anal Chem; 2010 Nov 1;82(21):9034-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolite identification in Synechococcus sp. PCC 7002 using untargeted stable isotope assisted metabolite profiling.
  • Untargeted metabolite profiling has the potential to identify numerous novel metabolites; however, de novo identification of metabolites from spectral features remains a challenge.
  • PCC 7002 was performed using normal phase liquid chromatography coupled to mass spectrometry (LC-MS).
  • Analysis of acquired MS/MS spectra against spectral database records led to the identification of a number of metabolites absent not only from the reconstructed draft metabolic network of Synechococcus sp.
  • PCC 7002 but not included in databases of metabolism (MetaCyc or KEGG).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20945921.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


44. Moslavac S, Reisinger V, Berg M, Mirus O, Vosyka O, Plöscher M, Flores E, Eichacker LA, Schleiff E: The proteome of the heterocyst cell wall in Anabaena sp. PCC 7120. Biol Chem; 2007 Aug;388(8):823-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The proteome of the heterocyst cell wall in Anabaena sp. PCC 7120.
  • Anabaena sp. PCC 7120 is a filamentous cyanobacterium that serves as a model to analyze prokaryotic cell differentiation, evolutionary development of plastids, and the regulation of nitrogen fixation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17655501.001).
  • [ISSN] 1431-6730
  • [Journal-full-title] Biological chemistry
  • [ISO-abbreviation] Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Proteome; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


45. Saxena RK, Raghuvanshi R, Singh S, Bisen PS: Iron induced metabolic changes in the diazotrophic cyanobacterium Anabaena PCC 7120. Indian J Exp Biol; 2006 Oct;44(10):849-51
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iron induced metabolic changes in the diazotrophic cyanobacterium Anabaena PCC 7120.
  • Iron induced changes in growth, N2-fixation, CO2 fixation and photosynthetic activity were studied in a diazotrophic cyanobacterium Anabaena PCC 7120.
  • Iron at 50 microM concentration supported the maximum growth, heterocyst frequency, CO2 fixation, photosystem I (PS I), photosystem II (PS II) and nitrogenase activities in the organism.
  • Higher concentration of iron inhibited these processes.

  • MedlinePlus Health Information. consumer health - Iron.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131917.001).
  • [ISSN] 0019-5189
  • [Journal-full-title] Indian journal of experimental biology
  • [ISO-abbreviation] Indian J. Exp. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 1406-65-1 / Chlorophyll; 142M471B3J / Carbon Dioxide; E1UOL152H7 / Iron; YF5Q9EJC8Y / chlorophyll a
  •  go-up   go-down


46. Mimuro M, Yokono M, Akimoto S: Variations in photosystem I properties in the primordial cyanobacterium Gloeobacter violaceus PCC 7421. Photochem Photobiol; 2010 Jan-Feb;86(1):62-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations in photosystem I properties in the primordial cyanobacterium Gloeobacter violaceus PCC 7421.
  • We compared the optical properties of the trimeric photosystem (PS) I complexes of the primordial cyanobacterium Gloeobacter violaceus PCC 7421 with those of Synechocystis sp. PCC 6803.
  • The energy transfer kinetics in the antennae at physiological temperatures were very similar between the two species due to the thermal equilibrium within the antenna; however, they differed at 77 K where energy transfer to Red Chls was clearly observed in Synechocystis sp. PCC 6803.
  • [MeSH-major] Cyanobacteria / chemistry. Photosystem I Protein Complex / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19769578.001).
  • [ISSN] 1751-1097
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosystem I Protein Complex
  •  go-up   go-down


47. Tabei Y, Okada K, Tsuzuki M: Sll1330 controls the expression of glycolytic genes in Synechocystis sp. PCC 6803. Biochem Biophys Res Commun; 2007 Apr 20;355(4):1045-50
Hazardous Substances Data Bank. GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sll1330 controls the expression of glycolytic genes in Synechocystis sp. PCC 6803.
  • PCC 6803, one can find many putative genes for two-component response regulators that include a helix-turn-helix DNA-binding domain.
  • PCC 6803 genome each encodes two isozymes for these five glycolytic genes, suggesting that each of the two isozymes is regulated by Sll1330 at the mRNA level.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17331473.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / DNA, Bacterial; 0 / RNA, Messenger; IY9XDZ35W2 / Glucose
  •  go-up   go-down


48. van de Meene AM, Hohmann-Marriott MF, Vermaas WF, Roberson RW: The three-dimensional structure of the cyanobacterium Synechocystis sp. PCC 6803. Arch Microbiol; 2006 Jan;184(5):259-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The three-dimensional structure of the cyanobacterium Synechocystis sp. PCC 6803.
  • PCC 6803 we investigated the three-dimensional organization of the cytoplasm using standard transmission electron microscopy and electron tomography.
  • At some of these sites, the margins of thylakoid membranes associated closely along the external surface of rod-like structures termed thylakoid centers, which sometimes traversed nearly the entire periphery of the cell.
  • PCC 6803 using high-resolution bioimaging techniques and will allow future evaluation and comparison with gene-deletion mutants.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16320037.001).
  • [ISSN] 0302-8933
  • [Journal-full-title] Archives of microbiology
  • [ISO-abbreviation] Arch. Microbiol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR-00592
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  •  go-up   go-down


49. Gotoh E: Drug-induced premature chromosome condensation (PCC) protocols: cytogenetic approaches in mitotic chromosome and interphase chromatin. Methods Mol Biol; 2009;523:83-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-induced premature chromosome condensation (PCC) protocols: cytogenetic approaches in mitotic chromosome and interphase chromatin.
  • Premature chromosome condensation (PCC) is an alternative method that has proved to be a unique and useful way in chromosome analysis.
  • Usually, PCC has been achieved following cell fusion mediated either by fusogenic viruses or by polyethylene glycol (cell-fusion PCC), but the cell-fusion PCC has several drawbacks.
  • The novel drug-induced PCC using protein phosphatase inhibitors was introduced about 10 years ago.
  • This method is much simple and easy even than the conventional mitotic chromosome preparation using colcemid block protocol and obtained PCC index (equivalent to mitotic index for metaphase chromosome) is much higher.
  • The drug-induced PCC has therefore proven the usefulness in cytogenetics and other cell biology fields.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19381920.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromatin; 0 / Oxazoles; 101932-71-2 / calyculin A
  •  go-up   go-down


50. Jansén T, Kidron H, Taipaleenmäki H, Salminen T, Mäenpää P: Transcriptional profiles and structural models of the Synechocystis sp. PCC 6803 Deg proteases. Photosynth Res; 2005 Jun;84(1-3):57-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional profiles and structural models of the Synechocystis sp. PCC 6803 Deg proteases.
  • PCC 6803 genome harbours a deg gene family consisting of three members, degP (htrA, slr1204), degQ (hhoA, sll1679) and degS (hhoB, sll1427).
  • PCC 6803 deg genes at the level of transcription and protein structures of the gene products to evaluate their hypothetical role in D1 protein turnover.
  • PCC 6803 Deg proteases were predicted based on an amino acid sequence alignment and comparison of the Deg crystal structures from human, Escherichia coli and Thermotoga maritima.
  • PCC 6803 Degs resemble more the Thermotoga maritima Deg enzyme structure than the Escherichia coli one.
  • PCC 6803 Deg proteases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16049755.001).
  • [ISSN] 0166-8595
  • [Journal-full-title] Photosynthesis research
  • [ISO-abbreviation] Photosyn. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.- / Peptide Hydrolases
  •  go-up   go-down


51. Liang CW, Zhang XW, Tian L, Qin S: Functional characterization of sll0659 from Synechocystis sp. PCC 6803. Indian J Biochem Biophys; 2008 Aug;45(4):275-7
Hazardous Substances Data Bank. BETA-CAROTENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional characterization of sll0659 from Synechocystis sp. PCC 6803.
  • PCC 6803 lacks a gene for the any known types of lycopene cyclase.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788479.001).
  • [ISSN] 0301-1208
  • [Journal-full-title] Indian journal of biochemistry & biophysics
  • [ISO-abbreviation] Indian J. Biochem. Biophys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Bacterial Proteins; 01YAE03M7J / beta Carotene; EC 5.5.- / Intramolecular Lyases; EC 5.5.- / lycopene cyclase-isomerase
  •  go-up   go-down


52. Agrawal MK, Zitt A, Bagchi D, Weckesser J, Bagchi SN, von Elert E: Characterization of proteases in guts of Daphnia magna and their inhibition by Microcystis aeruginosa PCC 7806. Environ Toxicol; 2005 Jun;20(3):314-22
Hazardous Substances Data Bank. CHYMOTRYPSIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of proteases in guts of Daphnia magna and their inhibition by Microcystis aeruginosa PCC 7806.
  • An extract from Microcystis aeruginosa strain PCC 7806 inhibited both types of D. magna proteases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc.
  • (PMID = 15892063.001).
  • [ISSN] 1520-4081
  • [Journal-full-title] Environmental toxicology
  • [ISO-abbreviation] Environ. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Toxins; 0 / Enzyme Inhibitors; 0 / Proteins; EC 3.4.- / Peptide Hydrolases; EC 3.4.21.1 / Chymotrypsin; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


53. Gotoh E: Visualizing the dynamics of chromosome structure formation coupled with DNA replication. Chromosoma; 2007 Oct;116(5):453-62
Hazardous Substances Data Bank. BROMODEOXYURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To visualize and identify the dynamics of chromosome structure formation and to elucidate the involvement of DNA replication in chromosome construction, Cy3-2'-deoxyuridine-5'-triphosphate direct-labeled active replicating DNA was observed in prematurely condensed chromosomes (PCCs) under a confocal scanning microscope utilized with drug-induced premature chromosome condensation (PCC) technique that facilitates the visualization of interphase chromatin as condensed chromosome form.
  • S-phase PCCs revealed clearly the drastic dynamics of chromosome formation that transits during S-phase from a 'cloudy nebula' to numerous numbers of 'beads on a string' and finally to 'striped arrays of banding structured chromosome' along with the progress of DNA replication.
  • Drug-induced PCC clearly provided the new insight that eukaryote DNA replication is tightly coupled with the chromosome condensation/compaction for the construction of the higher-ordered structure of the eukaryote chromosome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Somatic Cell Genet. 1983 Sep;9(5):533-47 [6623312.001]
  • [Cites] Curr Opin Genet Dev. 2003 Apr;13(2):185-90 [12672496.001]
  • [Cites] Cell. 2003 Mar 21;112(6):751-64 [12654243.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9350-9 [16227586.001]
  • [Cites] Exp Cell Res. 1999 Feb 25;247(1):176-88 [10047460.001]
  • [Cites] Cell. 1978 Oct;15(2):317-25 [719745.001]
  • [Cites] J Cell Biol. 1998 Mar 23;140(6):1285-95 [9508763.001]
  • [Cites] EMBO J. 2004 Jul 7;23(13):2651-63 [15215892.001]
  • [Cites] J Cell Physiol. 1970 Oct;76(2):151-7 [5533542.001]
  • [Cites] J Cell Sci. 1980 Dec;46:61-86 [7228916.001]
  • [Cites] Chromosoma. 1981;83(5):721-41 [7028418.001]
  • [Cites] J Cell Biol. 1999 Mar 8;144(5):813-21 [10085283.001]
  • [Cites] J Cell Sci. 1995 Sep;108 ( Pt 9):2927-35 [8537432.001]
  • [Cites] Planta. 2002 Jun;215(2):195-204 [12029468.001]
  • [Cites] J Cell Biol. 2004 Sep 13;166(6):775-85 [15353545.001]
  • [Cites] J Cell Physiol. 1977 Apr;91(1):131-41 [323270.001]
  • [Cites] Cell. 1980 Feb;19(2):527-36 [7357619.001]
  • [Cites] Nature. 1982 Jul 1;298(5869):100-2 [7088157.001]
  • [Cites] J Cell Biol. 1999 Aug 9;146(3):531-42 [10444063.001]
  • [Cites] Int J Radiat Biol. 1996 Nov;70(5):517-20 [8947532.001]
  • [Cites] Curr Opin Genet Dev. 2001 Apr;11(2):130-5 [11250134.001]
  • [Cites] Carcinogenesis. 1986 Dec;7(12):1975-80 [3022961.001]
  • [Cites] J Cell Biol. 1997 Dec 29;139(7):1597-610 [9412456.001]
  • [Cites] Bioessays. 2002 May;24(5):411-8 [12001264.001]
  • [Cites] J Cell Biol. 1987 Oct;105(4):1549-54 [2889739.001]
  • [Cites] J Histochem Cytochem. 2005 Mar;53(3):391-4 [15750027.001]
  • [Cites] Exp Cell Res. 1974 Jan;83(1):95-102 [4130365.001]
  • [Cites] Carcinogenesis. 1984 Oct;5(10):1277-85 [6488448.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11292-6 [16357135.001]
  • [Cites] Humangenetik. 1974;23(4):235-58 [4138742.001]
  • [Cites] Development. 2001 May;128(9):1697-707 [11290306.001]
  • [Cites] Nature. 1970 May 23;226(5247):717-22 [5443247.001]
  • [Cites] Mol Cell. 2003 Mar;11(3):557-69 [12667441.001]
  • [Cites] Chromosoma. 1974 Mar 14;45(2):121-31 [4837971.001]
  • [Cites] J Cell Sci. 1983 Nov;64:179-93 [6662858.001]
  • [Cites] Science. 1974 Jan 25;183(4122):330-2 [4128918.001]
  • [Cites] Mutagenesis. 1997 May;12 (3):175-7 [9175644.001]
  • [Cites] J Gen Virol. 2002 Oct;83(Pt 10):2377-83 [12237418.001]
  • [Cites] J Cell Physiol. 2006 Nov;209(2):297-304 [16810672.001]
  • [Cites] Annu Rev Genet. 1975;9:245-84 [55095.001]
  • [Cites] Chromosoma. 1984;90(5):389-93 [6510116.001]
  • [Cites] Curr Biol. 2000 Dec 14-28;10(24):1547-56 [11137005.001]
  • [Cites] J Cell Sci. 1989 Nov;94 ( Pt 3):471-7 [2632579.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18069-74 [16330769.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(15):5156-68 [11438670.001]
  • [Cites] Science. 1975 Jul 25;189(4199):291-3 [1145202.001]
  • [Cites] Int J Radiat Biol. 2005 May;81(5):379-85 [16076753.001]
  • [Cites] Exp Cell Res. 1971 Nov;69(1):97-105 [5124493.001]
  • [Cites] J Cell Sci Suppl. 1984;1:203-21 [6397471.001]
  • [Cites] Exp Cell Res. 2002 Jul 1;277(1):48-56 [12061816.001]
  • [Cites] Nature. 2000 Apr 6;404(6778):625-8 [10766248.001]
  • [Cites] J Cell Biol. 2003 Mar 3;160(5):685-97 [12604593.001]
  • [Cites] J Cell Sci. 2004 Oct 15;117(Pt 22):5353-65 [15466893.001]
  • [Cites] Int J Radiat Biol. 1999 Sep;75(9):1129-35 [10528921.001]
  • [Cites] Mol Biol Cell. 2003 Jun;14(6):2206-15 [12808023.001]
  • [Cites] Exp Cell Res. 1986 Aug;165(2):291-7 [3720850.001]
  • [Cites] J Cell Biol. 1984 Jul;99(1 Pt 1):42-52 [6736132.001]
  • [Cites] J Cell Biol. 1998 Dec 14;143(6):1415-25 [9852140.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):664-71 [14644190.001]
  • [Cites] J Cell Biol. 1979 Nov;83(2 Pt 1):403-27 [387806.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 2;261(2):317-25 [10425184.001]
  • [Cites] J Cell Biol. 1992 Mar;116(5):1095-110 [1740468.001]
  • [Cites] Cell. 1993 Apr 23;73(2):361-73 [8097433.001]
  • [Cites] Science. 1999 Jun 11;284(5421):1790-5 [10364545.001]
  • [Cites] J Cell Sci. 1987 Dec;88 ( Pt 5):669-78 [2459146.001]
  • [Cites] Mutagenesis. 2003 Nov;18(6):539-43 [14614190.001]
  • [Cites] Exp Cell Res. 1986 Nov;167(1):1-15 [3530789.001]
  • [Cites] Chromosoma. 2000 Mar;108(8):471-84 [10794569.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1993;58:777-92 [7525149.001]
  • [Cites] Exp Cell Res. 1976 Jul;100(2):219-22 [939249.001]
  • [Cites] Trends Genet. 1998 Jun;14(6):244-7 [9635408.001]
  • [Cites] J Cell Biol. 1980 Oct;87(1):285-91 [7419597.001]
  • [Cites] Cell. 1979 Aug;17(4):849-58 [487432.001]
  • [Cites] J Theor Biol. 1984 Nov 21;111(2):355-67 [6513575.001]
  • [Cites] Hum Genet. 1998 Feb;102(2):241-51 [9521598.001]
  • [Cites] Exp Cell Res. 1996 Aug 1;226(2):328-35 [8806436.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):17092-100 [11279043.001]
  • [Cites] J Cell Biol. 1989 Jan;108(1):1-11 [2910875.001]
  • [Cites] Nature. 2000 Apr 6;404(6778):622-5 [10766247.001]
  • [Cites] Int J Radiat Biol. 1998 Oct;74(4):457-62 [9798956.001]
  • (PMID = 17503067.001).
  • [ISSN] 0009-5915
  • [Journal-full-title] Chromosoma
  • [ISO-abbreviation] Chromosoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / 3'-deoxy-5-(cyanine dye 3)uridine 5'-trisphosphate; 0 / Carbocyanines; 0 / Chromatin; 0 / Deoxyuracil Nucleotides; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


54. Kim JA, Han GC, Lim M, You KS, Ryu M, Ahn JW, Fujita T, Kim H: Effect of hydraulic activity on crystallization of precipitated calcium carbonate (PCC) for eco-friendly paper. Int J Mol Sci; 2009 Nov;10(11):4954-62
Hazardous Substances Data Bank. CALCIUM CARBONATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of hydraulic activity on crystallization of precipitated calcium carbonate (PCC) for eco-friendly paper.
  • Wt% of aragonite, a CaCO(3) polymorph, increased with higher hydraulic activity ( degrees C) of limestone in precipitated calcium carbonate (PCC) from the lime-soda process (Ca(OH)(2)-NaOH-Na(2)CO(3)).
  • The crystallization of PCC is more dependent on the hydraulic activity of limestone than CaO content, a factor commonly used to classify limestone ores according to quality.
  • The results could be effectively applied to the determination of polymorphs in synthetic PCC for eco-friendly paper manufacture.
  • [MeSH-minor] Calcium Compounds / chemistry. Crystallization. Industry. Oxides / chemistry. Temperature

  • Hazardous Substances Data Bank. CALCIUM COMPOUNDS .
  • Hazardous Substances Data Bank. CALCIUM OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Talanta. 1996 Sep;43(9):1497-509 [18966629.001]
  • (PMID = 20087470.001).
  • [ISSN] 1422-0067
  • [Journal-full-title] International journal of molecular sciences
  • [ISO-abbreviation] Int J Mol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Calcium Compounds; 0 / Oxides; C7X2M0VVNH / lime; H0G9379FGK / Calcium Carbonate
  • [Other-IDs] NLM/ PMC2808016
  • [Keywords] NOTNLM ; aragonite / calcite / crystallization / eco-friendly paper / hydraulic activity / limestone / precipitated calcium carbonate (PCC)
  • [General-notes] NLM/ Original DateCompleted: 20100628
  •  go-up   go-down


55. Huttner HB, Schellinger PD, Hartmann M, Köhrmann M, Juettler E, Wikner J, Mueller S, Meyding-Lamade U, Strobl R, Mansmann U, Schwab S, Steiner T: Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke; 2006 Jun;37(6):1465-70
MedlinePlus Health Information. consumer health - Vitamin K.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates.
  • The aim of the present study was to compare the acute treatment strategies of OAT-associated ICH using vitamin K (VAK), fresh frozen plasma (FFP), and prothrombin complex concentrates (PCCs) with regard to hematoma growth and outcome.
  • (1) patients who received PCCs alone or in combination with FFP or VAK (n=31), (2) patients treated with FFP alone or in combination with VAK (n=18), and (3) patients who received VAK as a monotherapy (n=6).
  • Incidence and extent of hematoma growth were significantly lower in patients receiving PCCs (19%/44%) compared with FFP (33%/54%) and VAK (50%/59%).
  • However, this effect was no longer seen between PCC- and FFP-treated patients if international normalized ratio (INR) was completely reversed within 2 hours after admission.
  • Predictors for hematoma growth were an increased INR after 2 hours, whereas administration of PCCs was significantly protective in multivariate analyses.
  • CONCLUSIONS: Overall, PCC was associated with a reduced incidence and extent of hematoma growth compared with FFP and VAK.
  • [MeSH-major] Anticoagulants / adverse effects. Blood Coagulation Factors / therapeutic use. Blood Component Transfusion. Cerebral Hemorrhage / therapy. Critical Care. Hematoma / therapy. Vitamin K / therapeutic use
  • [MeSH-minor] Administration, Oral. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Plasma. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Prothrombin.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Critical Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16675739.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Blood Coagulation Factors; 12001-79-5 / Vitamin K; 37224-63-8 / prothrombin complex concentrates
  •  go-up   go-down


56. Li RG, Yu X, Zhao JD: [Expression and characterization of FNRD in cyanobacterium Synechococcus sp. PCC 7002]. Wei Sheng Wu Xue Bao; 2005 Oct;45(5):716-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and characterization of FNRD in cyanobacterium Synechococcus sp. PCC 7002].
  • PCC 7002, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16342762.001).
  • [ISSN] 0001-6209
  • [Journal-full-title] Wei sheng wu xue bao = Acta microbiologica Sinica
  • [ISO-abbreviation] Wei Sheng Wu Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.18.1.2 / Ferredoxin-NADP Reductase
  •  go-up   go-down


57. Watanabe S, Kobayashi T, Saito M, Sato M, Nimura-Matsune K, Chibazakura T, Taketani S, Nakamoto H, Yoshikawa H: Studies on the role of HtpG in the tetrapyrrole biosynthesis pathway of the cyanobacterium Synechococcus elongatus PCC 7942. Biochem Biophys Res Commun; 2007 Jan 5;352(1):36-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studies on the role of HtpG in the tetrapyrrole biosynthesis pathway of the cyanobacterium Synechococcus elongatus PCC 7942.
  • In cyanobacterium Synechococcus elongatus PCC 7942, we observed that htpG-overexpression caused remarkable growth inhibition.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107658.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / HSP90 Heat-Shock Proteins; 0 / Tetrapyrroles; 134548-76-8 / HtpG protein, bacteria; EC 4.1.1.37 / Uroporphyrinogen Decarboxylase
  •  go-up   go-down


58. Gao B, Sun Y, Liu Z, Meng F, Shi B, Liu Y, Xu Z: A logistic regression model for predicting malignant pheochromocytomas. J Cancer Res Clin Oncol; 2008 Jun;134(6):631-4
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A logistic regression model for predicting malignant pheochromocytomas.
  • It is well known that no single histological feature is diagnostic for malignant pheochromocytomas (PCCs).
  • So we developed a logistic model based on a series of clinical and pathological features to predict malignance in PCCs, and evaluated its diagnostic performance.
  • In all 130 cases with malignant or benign PCCs, 15 predictive variables were observed and entered in the logistic regression analysis in a backward stepwise way.
  • High cellularity had the highest odds ratio (OR), followed by spindle cell (>10% of tumor volume), atypical mitotic figure, periadrenal adipose tissue invasion, mitotic figures [>3/10 high-power field (HPF)], cellular monotony, capsular invasion, vascular invasion, and central or confluent tumor necrosis.
  • High cellularity, spindle cell (>10% of tumor volume) and atypical mitotic figure were selected to built a logistic model.
  • The application of the model can benefit the clinical management decision for patients with PCCs.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Pheochromocytoma / diagnosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Braz J Med Biol Res. 2000 Oct;33(10):1177-89 [11004718.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1409-10 [15371856.001]
  • [Cites] Stat Med. 2004 Aug 30;23(16):2567-86 [15287085.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5615-9 [11701743.001]
  • [Cites] Hinyokika Kiyo. 2005 Apr;51(4):291-6 [15912793.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):611-20 [17297554.001]
  • [Cites] Br J Surg. 1979 Jul;66(7):456-65 [466037.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:533-40 [17102122.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):364-72 [15671347.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1235-46 [12368197.001]
  • [Cites] Surg Gynecol Obstet. 1982 Jun;154(6):801-18 [7079921.001]
  • [Cites] Ann N Y Acad Sci. 2006 Aug;1073:541-56 [17102123.001]
  • [Cites] Obstet Gynecol. 2000 Jul;96(1):75-80 [10862846.001]
  • [Cites] J Surg Res. 2005 Oct;128(2):199-206 [16140341.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2231-5 [11344232.001]
  • [Cites] J Clin Epidemiol. 2005 May;58(5):475-83 [15845334.001]
  • [Cites] Cancer. 1977 Nov;40(5):1987-2004 [922654.001]
  • [Cites] Neurol Res. 2005 Oct;27(7):747-54 [16197812.001]
  • (PMID = 17999082.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Shimojima M, Tsuchiya M, Ohta H: Temperature-dependent hyper-activation of monoglucosyldiacylglycerol synthase is post-translationally regulated in Synechocystis sp. PCC 6803. FEBS Lett; 2009 Jul 21;583(14):2372-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temperature-dependent hyper-activation of monoglucosyldiacylglycerol synthase is post-translationally regulated in Synechocystis sp. PCC 6803.
  • PCC 6803 was examined by measuring MGlcDG synthase (Sll1377) activity.
  • PCC 6803, whereas the Sll1377 protein level remained unchanged, suggesting that the activity is post-translationally regulated without covalent modification of Sll1377 by soluble enzymes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549521.001).
  • [ISSN] 1873-3468
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Glycolipids; 0 / glucosyl diacylglycerol; EC 2.4.1.- / Glucosyltransferases; EC 2.4.1.157 / 1,2-diacylglycerol 3-glucosyltransferase
  •  go-up   go-down


60. Brecht M, Radics V, Nieder JB, Studier H, Bittl R: Red antenna states of photosystem I from Synechocystis PCC 6803. Biochemistry; 2008 May 20;47(20):5536-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Red antenna states of photosystem I from Synechocystis PCC 6803.
  • Emission spectra of single PSI complexes from the cyanobacterium Synechocystis PCC 6803 show zero-phonon lines (ZPLs) as well as broad intensity distributions without ZPLs.
  • The broad distributions dominating the red side of the spectra are made up of a low number of emitters assigned to the red-most pool C714.
  • The properties of F699 show close relation to those of F698 in Synechococcus PCC 7002 and C708 in Thermosynechococcus elongatus.
  • Furthermore, a high similarity is found between the C714 pool in Synechocystis PCC 6803 and C708 in Synechococcus PCC 7002 as well as C719 in T. elongatus.
  • [MeSH-major] Photosystem I Protein Complex / chemistry. Photosystem I Protein Complex / metabolism. Synechocystis / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18429622.001).
  • [ISSN] 1520-4995
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosystem I Protein Complex
  •  go-up   go-down


61. Zang X, Liu B, Liu S, Arunakumara KK, Zhang X: Optimum conditions for transformation of Synechocystis sp. PCC 6803. J Microbiol; 2007 Jun;45(3):241-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimum conditions for transformation of Synechocystis sp. PCC 6803.
  • This study was conducted to determine the optimal conditions for introduction of exogenous DNA into Synechocystis sp. PCC 6803.
  • Additionally, this study demonstrated that the higher plasmid concentration and longer homologous recombining fragments resulted in a greater number of transformants.
  • For successful transformation, the lowest concentration of plasmid was 0.02 microg/ml, and the shortest homologous recombining fragment was 0.2 kb.
  • PCC 6803 in the logarithmic growth phase resulted in two-fold higher transformation rate than that of the same organism when cells in the latent phase or the plateau phase were used for transformation.
  • PCC 6803, with EDTA (2 mM) for two days prior to transformation increased the transformation efficiency by 23%.

  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618230.001).
  • [ISSN] 1225-8873
  • [Journal-full-title] Journal of microbiology (Seoul, Korea)
  • [ISO-abbreviation] J. Microbiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Bacterial; 9G34HU7RV0 / Edetic Acid
  •  go-up   go-down


62. Cha EY, Park JS, Jeon S, Kong JS, Choi YK, Ryu JY, Park YI, Park YS: Functional characterization of the gene encoding UDP-glucose: tetrahydrobiopterin alpha-glucosyltransferase in Synechococcus sp. PCC 7942. J Microbiol; 2005 Apr;43(2):191-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional characterization of the gene encoding UDP-glucose: tetrahydrobiopterin alpha-glucosyltransferase in Synechococcus sp. PCC 7942.
  • PCC 7942 mutant resultant from a disruption in the gene encoding UDP-glucose: tetrahydrobiopterin alpha-glucosyltransferase (BGluT).
  • PCC 7942, BH4-glucoside might be involved in photosynthetic photoprotection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880096.001).
  • [ISSN] 1225-8873
  • [Journal-full-title] Journal of microbiology (Seoul, Korea)
  • [ISO-abbreviation] J. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Bacterial Proteins; EC 2.4.1.- / BGluT protein, Synechococcus sp. PCC 7942; EC 2.4.1.- / Glucosyltransferases
  •  go-up   go-down


63. Adamoli AN, Azevedo MR: [Patterns of physical activity of people with chronic mental and behavioral disorders]. Cien Saude Colet; 2009 Jan-Feb;14(1):243-51
MedlinePlus Health Information. consumer health - Mental Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Padrões de atividade física de pessoas com transtornos mentais e de comportamento.
  • Since physical activity (PA) is capable of improving both the quality of life and the prognosis for individuals with mental and behavioral disorders (MBD), the main purpose of this study was to analyze the PA patterns in individuals with MBD frequenting a Psychosocial Care Center (PCC) in the city of Pelotas.
  • The target population of this descriptive study consisted of individuals attended in any of the PCCs of Pelotas.
  • The sample was selected from six PCCs and comprised 85 patients and their relatives.
  • Men participated more in the PA offered by the PCC than women.
  • Therefore, incorporation of PA in PCC seems to be a feasible initiative for supporting the treatment of these patients and would offer a unique opportunity for the patients to engage in supervised and structured PA programs.
  • [MeSH-minor] Adult. Chronic Disease. Female. Humans. Life Style. Male. Middle Aged

  • Genetic Alliance. consumer health - Behavioral Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19142328.001).
  • [ISSN] 1678-4561
  • [Journal-full-title] Ciência & saúde coletiva
  • [ISO-abbreviation] Cien Saude Colet
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


64. Zilliges Y, Kehr JC, Mikkat S, Bouchier C, de Marsac NT, Börner T, Dittmann E: An extracellular glycoprotein is implicated in cell-cell contacts in the toxic cyanobacterium Microcystis aeruginosa PCC 7806. J Bacteriol; 2008 Apr;190(8):2871-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An extracellular glycoprotein is implicated in cell-cell contacts in the toxic cyanobacterium Microcystis aeruginosa PCC 7806.
  • Differences in the cellular aggregation of M. aeruginosa PCC 7806 and a microcystin-deficient Delta mcyB mutant guided the discovery of a surface-exposed protein that shows increased abundance in PCC 7806 mutants deficient in microcystin production compared to the abundance of this protein in the wild type.
  • Mass spectrometric and immunoblot analyses revealed that the protein, designated microcystin-related protein C (MrpC), is posttranslationally glycosylated, suggesting that it may be a potential target of a putative O-glycosyltransferase of the SPINDLY family encoded downstream of the mrpC gene.
  • Immunofluorescence microscopy detected MrpC at the cell surface, suggesting an involvement of the protein in cellular interactions in strain PCC 7806.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol. 2000 Oct;7(10):753-64 [11033079.001]
  • [Cites] Environ Microbiol. 2007 Apr;9(4):965-70 [17359268.001]
  • [Cites] Microbiology. 2001 Nov;147(Pt 11):3113-9 [11700361.001]
  • [Cites] Mol Microbiol. 2002 Jan;43(1):147-57 [11849543.001]
  • [Cites] Proteomics. 2003 Apr;3(4):363-79 [12687605.001]
  • [Cites] Mol Microbiol. 2003 May;48(3):737-51 [12694618.001]
  • [Cites] Mol Microbiol. 2003 Aug;49(3):833-47 [12864863.001]
  • [Cites] J Bacteriol. 2003 Nov;185(22):6658-65 [14594840.001]
  • [Cites] Arch Microbiol. 2003 Dec;180(6):402-10 [14551674.001]
  • [Cites] Syst Appl Microbiol. 2004 Sep;27(5):592-602 [15490561.001]
  • [Cites] Methods Enzymol. 1988;167:3-27 [3148836.001]
  • [Cites] Microbiol Rev. 1994 Mar;58(1):94-144 [8177173.001]
  • [Cites] J Biol Chem. 1995 Jun 2;270(22):13197-203 [7768917.001]
  • [Cites] Microbiology. 1995 May;141 ( Pt 5):1247-54 [7773418.001]
  • [Cites] J Bacteriol. 1996 Jan;178(2):372-6 [8550455.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6504-9 [8692845.001]
  • [Cites] Mol Microbiol. 1996 Jan;19(2):379-87 [8825782.001]
  • [Cites] FEMS Microbiol Lett. 1996 Nov 15;145(1):107-11 [8931334.001]
  • [Cites] J Biol Chem. 1996 Dec 6;271(49):31391-8 [8940148.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9292-6 [8799194.001]
  • [Cites] Mol Microbiol. 1997 Nov;26(4):779-87 [9427407.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):873-8 [9516222.001]
  • [Cites] Mol Microbiol. 1998 Jun;28(6):1283-93 [9680216.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Appl Environ Microbiol. 2004 Nov;70(11):6370-8 [15528494.001]
  • [Cites] Microbiology. 2005 May;151(Pt 5):1313-23 [15870442.001]
  • [Cites] Sci STKE. 2005 Nov 29;2005(312):re13 [16317114.001]
  • [Cites] Mol Microbiol. 2006 Feb;59(3):893-906 [16420359.001]
  • [Cites] Glycoconj J. 1997 Jan;14(1):3-11 [9076508.001]
  • [Cites] Mol Microbiol. 1997 Nov;26(4):699-708 [9427400.001]
  • [Cites] J Bacteriol. 2006 Mar;188(5):1798-807 [16484190.001]
  • [Cites] Mol Nutr Food Res. 2006 Jan;50(1):7-17 [16304634.001]
  • [Cites] Proteomics. 2006 May;6(9):2733-45 [16572470.001]
  • [Cites] Appl Environ Microbiol. 2001 Nov;67(11):5069-76 [11679328.001]
  • (PMID = 18281396.001).
  • [ISSN] 1098-5530
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adhesins, Bacterial; 0 / Glycoproteins; 0 / Microcystins
  • [Other-IDs] NLM/ PMC2293267
  •  go-up   go-down


65. Fiedler B, Börner T, Wilde A: Phototaxis in the cyanobacterium Synechocystis sp. PCC 6803: role of different photoreceptors. Photochem Photobiol; 2005 Nov-Dec;81(6):1481-8
Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phototaxis in the cyanobacterium Synechocystis sp. PCC 6803: role of different photoreceptors.
  • PCC 6803 was suggested as a part of a light-stimulated signal transduction chain inhibiting movement toward blue light.
  • Analysis of mutants lacking cysteine-129 in the N-terminal chromophore binding domain indicated that this domain is also important for Cph2 function or folding of the protein.
  • PCC 6803 genome were inactivated in wild-type and cph2 knockout mutant background.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354116.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Cph2 protein, bacteria; 0 / Cryptochromes; 0 / Flavoproteins; 0 / Photoreceptors, Microbial; 11121-56-5 / Phytochrome
  •  go-up   go-down


66. Maeda H, Sakuragi Y, Bryant DA, Dellapenna D: Tocopherols protect Synechocystis sp. strain PCC 6803 from lipid peroxidation. Plant Physiol; 2005 Jul;138(3):1422-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tocopherols protect Synechocystis sp. strain PCC 6803 from lipid peroxidation.
  • To test this hypothesis, tocopherol-deficient mutants of Synechocystis sp. strain PCC 6803 (slr1736 and slr1737 mutants) were challenged with a series of reactive oxygen species-generating and lipid peroxidation-inducing chemicals in combination with high-light (HL) intensity stress.
  • However, the mutants showed enhanced sensitivity to linoleic or linolenic acid treatments in combination with HL, consistent with tocopherols playing a crucial role in protecting Synechocystis sp. strain PCC 6803 cells from lipid peroxidation.
  • The tocopherol-deficient mutants were also more susceptible to HL treatment in the presence of sublethal levels of norflurazon, an inhibitor of carotenoid synthesis, suggesting carotenoids and tocopherols functionally interact or have complementary or overlapping roles in protecting Synechocystis sp. strain PCC 6803 from lipid peroxidation and HL stress.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Jan 5;276(1):306-14 [11024039.001]
  • [Cites] FEBS Lett. 1999 Jul 9;454(3):247-51 [10431816.001]
  • [Cites] Plant Cell. 2001 Apr;13(4):793-806 [11283337.001]
  • [Cites] Plant Physiol. 2001 Apr;125(4):1558-66 [11299337.001]
  • [Cites] FEBS Lett. 2001 Jun 15;499(1-2):15-20 [11418103.001]
  • [Cites] FEBS Lett. 2001 Jun 15;499(1-2):32-6 [11418106.001]
  • [Cites] Plant Physiol. 2001 Nov;127(3):1113-24 [11706191.001]
  • [Cites] J Agric Food Chem. 2001 Nov;49(11):5270-2 [11714315.001]
  • [Cites] FEBS Lett. 2002 Jan 30;511(1-3):1-5 [11821038.001]
  • [Cites] FEBS Lett. 2002 Apr 10;516(1-3):156-60 [11959123.001]
  • [Cites] Biol Chem. 2002 Mar-Apr;383(3-4):457-65 [12033435.001]
  • [Cites] FEBS Lett. 2002 Jul 17;523(1-3):177-81 [12123828.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12495-500 [12213958.001]
  • [Cites] J Bacteriol. 2002 Dec;184(24):6845-58 [12446635.001]
  • [Cites] Biochim Biophys Acta. 2003 Mar 17;1620(1-3):245-51 [12595095.001]
  • [Cites] Plant Cell. 2003 Apr;15(4):992-1008 [12671093.001]
  • [Cites] Plant Physiol. 2003 Aug;132(4):2184-95 [12913173.001]
  • [Cites] Annu Rev Plant Biol. 2003;54:93-107 [14502986.001]
  • [Cites] Plant Cell. 2003 Oct;15(10):2343-56 [14508009.001]
  • [Cites] Plant Physiol. 2003 Oct;133(2):930-40 [14512521.001]
  • [Cites] J Biol Chem. 2004 Feb 20;279(8):6337-44 [14665619.001]
  • [Cites] Plant Cell. 2004 Jun;16(6):1419-32 [15155886.001]
  • [Cites] J Bacteriol. 2004 Sep;186(17):5621-8 [15317766.001]
  • [Cites] Plant Physiol. 2004 Sep;136(1):2855-61 [15347790.001]
  • [Cites] Anal Biochem. 1978 Oct 1;90(1):420-6 [727482.001]
  • [Cites] Arch Biochem Biophys. 1989 Mar;269(2):390-9 [2919876.001]
  • [Cites] J Biol Chem. 2005 Jan 7;280(1):840-6 [15509585.001]
  • [Cites] Plant Physiol. 2005 Feb;137(2):713-23 [15665245.001]
  • [Cites] J Exp Bot. 2000 Aug;51(349):1363-70 [10944149.001]
  • [Cites] Mol Membr Biol. 2000 Jul-Sep;17(3):143-56 [11128973.001]
  • [Cites] Biochemistry. 1995 May 2;34(17):5754-61 [7727436.001]
  • [Cites] Arch Biochem Biophys. 1995 Nov 10;323(2):343-51 [7487097.001]
  • [Cites] Lipids. 1996 May;31(5):535-9 [8727647.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7534-9 [8755509.001]
  • [Cites] DNA Res. 1996 Jun 30;3(3):109-36 [8905231.001]
  • [Cites] Arch Biochem Biophys. 1997 Mar 1;339(1):157-64 [9056245.001]
  • [Cites] J Biol Chem. 1997 Apr 11;272(15):9728-33 [9092504.001]
  • [Cites] Arch Biochem Biophys. 1997 Apr 15;340(2):219-30 [9143325.001]
  • [Cites] Arch Biochem Biophys. 1998 Jan 15;349(2):281-9 [9448716.001]
  • [Cites] Appl Environ Microbiol. 1998 Jul;64(7):2361-6 [9647800.001]
  • [Cites] Science. 1998 Dec 11;282(5396):2098-100 [9851934.001]
  • [Cites] FEBS Lett. 1999 Mar 26;447(2-3):269-73 [10214959.001]
  • [Cites] FASEB J. 1999 Jul;13(10):1145-55 [10385606.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8762-7 [10411949.001]
  • [ErratumIn] Plant Physiol. 2006 Apr;140(4):1522
  • (PMID = 15965015.001).
  • [ISSN] 0032-0889
  • [Journal-full-title] Plant physiology
  • [ISO-abbreviation] Plant Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipid Peroxides; 0 / Reactive Oxygen Species; 1406-65-1 / Chlorophyll; 1406-66-2 / Tocopherols; 36-88-4 / Carotenoids
  • [Other-IDs] NLM/ PMC1176414
  •  go-up   go-down


67. Xu D, Liu X, Guo C, Zhao J: Methylglyoxal detoxification by an aldo-keto reductase in the cyanobacterium Synechococcus sp. PCC 7002. Microbiology; 2006 Jul;152(Pt 7):2013-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylglyoxal detoxification by an aldo-keto reductase in the cyanobacterium Synechococcus sp. PCC 7002.
  • An AKR gene, sakR1, was identified in the cyanobacterium Synechococcus sp. PCC 7002.
  • A mutant strain with sakR1 inactivated was sensitive to glycerol, a carbon source that can support heterotrophic growth of Synechococcus sp. PCC 7002.
  • Based on immunoblotting, SakR1 was not upregulated at an increased cellular methylglyoxal concentration.
  • A pH-dependent enzyme-activity profile suggested that SakR1 activity could be regulated by cellular pH in Synechococcus sp. PCC 7002.

  • Hazardous Substances Data Bank. METHYL GLYOXAL .
  • StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16804176.001).
  • [ISSN] 1350-0872
  • [Journal-full-title] Microbiology (Reading, England)
  • [ISO-abbreviation] Microbiology (Reading, Engl.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 722KLD7415 / Pyruvaldehyde; EC 1.1.- / Alcohol Oxidoreductases; EC 1.1.1.184 / carbonyl reductase (NADPH); EC 1.1.1.21 / Aldehyde Reductase
  •  go-up   go-down


68. Marbouty M, Saguez C, Cassier-Chauvat C, Chauvat F: Characterization of the FtsZ-interacting septal proteins SepF and Ftn6 in the spherical-celled cyanobacterium Synechocystis strain PCC 6803. J Bacteriol; 2009 Oct;191(19):6178-85

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of the FtsZ-interacting septal proteins SepF and Ftn6 in the spherical-celled cyanobacterium Synechocystis strain PCC 6803.
  • Here, we characterized SepF and Ftn6, two novel septal proteins, in the spherical-celled strain Synechocystis PCC 6803.
  • Both proteins were found to be indispensable to Synechocystis sp. strain PCC 6803.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plant Mol Biol. 1993 Nov;23(4):905-9 [8251644.001]
  • [Cites] J Bacteriol. 1989 Jun;171(6):3449-57 [2498291.001]
  • [Cites] DNA Res. 1996 Jun 30;3(3):109-36 [8905231.001]
  • [Cites] Microbiol Mol Biol Rev. 1999 Mar;63(1):106-27 [10066832.001]
  • [Cites] J Bacteriol. 2004 Dec;186(24):8326-36 [15576782.001]
  • [Cites] Mol Microbiol. 2005 Apr;56(1):126-43 [15773984.001]
  • [Cites] Curr Biol. 2005 Jul 12;15(13):R514-26 [16005287.001]
  • [Cites] Plant J. 2005 Sep;43(6):811-23 [16146521.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Nov;6(11):862-71 [16227976.001]
  • [Cites] Mol Microbiol. 2006 Feb;59(3):989-99 [16420366.001]
  • [Cites] Int Rev Cytol. 2006;253:27-94 [17098054.001]
  • [Cites] Nat Protoc. 2007;2(4):924-32 [17446874.001]
  • [Cites] Annu Rev Biochem. 2007;76:539-62 [17328675.001]
  • [Cites] Biochemistry. 2007 Sep 25;46(38):11013-22 [17718511.001]
  • [Cites] Nat Rev Microbiol. 2008 Feb;6(2):162-8 [18157153.001]
  • [Cites] Mol Microbiol. 2008 May;68(3):720-35 [18394147.001]
  • [Cites] Curr Opin Microbiol. 2008 Apr;11(2):94-9 [18396093.001]
  • [Cites] Curr Opin Biotechnol. 2008 Jun;19(3):235-40 [18539450.001]
  • [Cites] J Biol Chem. 2008 Nov 7;283(45):31116-24 [18782755.001]
  • [Cites] Curr Opin Plant Biol. 2008 Dec;11(6):577-84 [18990608.001]
  • [Cites] Chem Soc Rev. 2009 Jan;38(1):52-61 [19088964.001]
  • [Cites] Trends Biotechnol. 2009 Jan;27(1):45-52 [19022511.001]
  • [Cites] Nature. 2001 Aug 9;412(6847):635-8 [11493920.001]
  • [Cites] EMBO J. 2002 Feb 15;21(4):685-93 [11847116.001]
  • [Cites] Appl Microbiol Biotechnol. 2002 Feb;58(2):123-37 [11876404.001]
  • [Cites] J Bacteriol. 2002 Oct;184(19):5524-8 [12218043.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Mar;67(1):52-65, table of contents [12626683.001]
  • [Cites] Mol Microbiol. 2004 May;52(4):1145-58 [15130131.001]
  • [Cites] Mol Microbiol. 2004 Jul;53(1):65-80 [15225304.001]
  • [Cites] Curr Opin Genet Dev. 1993 Dec;3(6):884-90 [8118213.001]
  • (PMID = 19648234.001).
  • [ISSN] 1098-5530
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Recombinant Fusion Proteins
  • [Other-IDs] NLM/ PMC2747883
  •  go-up   go-down


69. Koyama K, Suzuki H, Noguchi T, Akimoto S, Tsuchiya T, Mimuro M: Oxygen evolution in the thylakoid-lacking cyanobacterium Gloeobacter violaceus PCC 7421. Biochim Biophys Acta; 2008 Apr;1777(4):369-78
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxygen evolution in the thylakoid-lacking cyanobacterium Gloeobacter violaceus PCC 7421.
  • The oxygen-evolving reactions of the thylakoid-lacking cyanobacterium Gloeobacter violaceus PCC 7421 were compared with those of Synechocystis sp. PCC 6803.
  • PCC 6803, the oxygen-evolving activities were similar.
  • [MeSH-major] Cyanobacteria / metabolism. Oxygen / metabolism. Photosystem II Protein Complex / metabolism

  • Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298941.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Cytochrome c Group; 0 / Photosystem II Protein Complex; 0 / PsbU protein, Synechocystis; 42Z2K6ZL8P / Manganese; 9064-80-6 / cytochrome C-550; S88TT14065 / Oxygen
  •  go-up   go-down


70. Dreher C, Hielscher R, Prodöhl A, Hellwig P, Schneider D: Characterization of two cytochrome b6 proteins from the cyanobacterium Gloeobacter violaceus PCC 7421. J Bioenerg Biomembr; 2010 Dec;42(6):517-26

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of two cytochrome b6 proteins from the cyanobacterium Gloeobacter violaceus PCC 7421.
  • In the genome of the untypical cyanobacterium Gloeobacter violaceus PCC 7421 two potential cytochrome b (6) proteins PetB1 and PetB2 are encoded.
  • [MeSH-minor] Amino Acid Sequence. Cytochrome b6f Complex / genetics. Cytochrome b6f Complex / metabolism. Electrophoresis, Polyacrylamide Gel. Heme / metabolism. Molecular Sequence Data. Mutagenesis. Operon / genetics. Sequence Alignment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20237831.001).
  • [ISSN] 1573-6881
  • [Journal-full-title] Journal of bioenergetics and biomembranes
  • [ISO-abbreviation] J. Bioenerg. Biomembr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytochromes b6; 0 / petD protein, cytochrome b(6)f complex; 42VZT0U6YR / Heme; 9035-40-9 / Cytochrome b6f Complex
  •  go-up   go-down


71. Suzuki E, Ohkawa H, Moriya K, Matsubara T, Nagaike Y, Iwasaki I, Fujiwara S, Tsuzuki M, Nakamura Y: Carbohydrate metabolism in mutants of the cyanobacterium Synechococcus elongatus PCC 7942 defective in glycogen synthesis. Appl Environ Microbiol; 2010 May;76(10):3153-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbohydrate metabolism in mutants of the cyanobacterium Synechococcus elongatus PCC 7942 defective in glycogen synthesis.
  • Mutants defective in each of these enzymes in Synechococcus elongatus PCC 7942 were constructed and characterized.
  • [MeSH-minor] Carbohydrates / analysis. Chlorophyll / analysis. Glucose-1-Phosphate Adenylyltransferase / genetics. Glucose-1-Phosphate Adenylyltransferase / metabolism. Glycogen Synthase / genetics. Glycogen Synthase / metabolism. Hydrogen Peroxide / pharmacology. Oxidative Stress / drug effects. Oxygen / analysis. Photosynthesis / drug effects. Phycocyanin / analysis. Sodium Chloride / pharmacology

  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bacteriol. 2001 Feb;183(4):1376-84 [11157951.001]
  • [Cites] FEMS Microbiol Rev. 2009 Mar;33(2):258-78 [18834454.001]
  • [Cites] Plant Physiol. 2001 Oct;127(2):459-72 [11598221.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 11;290(1):339-48 [11779175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):4109-14 [11891307.001]
  • [Cites] Biochemistry (Mosc). 2002 Apr;67(4):432-40 [11996656.001]
  • [Cites] FEMS Microbiol Lett. 2003 Jan 21;218(1):71-7 [12583900.001]
  • [Cites] J Bacteriol. 2003 Jun;185(12):3654-60 [12775703.001]
  • [Cites] Biotechnol Lett. 2003 Mar;25(5):391-6 [12882559.001]
  • [Cites] Annu Rev Plant Biol. 2003;54:207-33 [14502990.001]
  • [Cites] Biochem J. 2004 Oct 15;383(Pt 2):277-83 [15225123.001]
  • [Cites] Plant Physiol. 2004 Oct;136(2):3290-300 [15361582.001]
  • [Cites] J Biol Chem. 1981 Jul 10;256(13):6944-52 [6263926.001]
  • [Cites] Annu Rev Microbiol. 1984;38:419-58 [6093684.001]
  • [Cites] Methods Enzymol. 1987;153:215-31 [3123881.001]
  • [Cites] J Biol Chem. 1992 Nov 15;267(32):22944-50 [1429645.001]
  • [Cites] Plant Cell Physiol. 2005 Mar;46(3):539-45 [15695453.001]
  • [Cites] DNA Res. 2005;12(2):103-15 [16303742.001]
  • [Cites] Proteomics. 2006 May;6(9):2733-45 [16572470.001]
  • [Cites] Biochim Biophys Acta. 2007 Feb;1767(2):161-9 [17274945.001]
  • [Cites] Biochim Biophys Acta. 2007 May;1770(5):763-73 [17321685.001]
  • [Cites] Photosynth Res. 2007 Jul-Sep;93(1-3):55-67 [17211581.001]
  • [Cites] Mol Biol Evol. 2008 Mar;25(3):536-48 [18093994.001]
  • [Cites] Curr Opin Cell Biol. 2001 Aug;13(4):399-404 [11454443.001]
  • (PMID = 20363800.001).
  • [ISSN] 1098-5336
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbohydrates; 11016-15-2 / Phycocyanin; 1406-65-1 / Chlorophyll; 451W47IQ8X / Sodium Chloride; 9005-79-2 / Glycogen; BBX060AN9V / Hydrogen Peroxide; EC 2.4.1.11 / Glycogen Synthase; EC 2.7.7.27 / Glucose-1-Phosphate Adenylyltransferase; S88TT14065 / Oxygen; YF5Q9EJC8Y / chlorophyll a
  • [Other-IDs] NLM/ PMC2869141
  •  go-up   go-down


72. Fu J, Xu X: The functional divergence of two glgP homologues in Synechocystis sp. PCC 6803. FEMS Microbiol Lett; 2006 Jul;260(2):201-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The functional divergence of two glgP homologues in Synechocystis sp. PCC 6803.
  • Glycogen phosphorylase (GlgP, EC 2.4.1.1) catalyzes the cleavage of glycogen into glucose-1-phosphate (Glc-1-P), the first step in glycogen catabolism.
  • PCC 6803, a unicellular cyanobacterium: sll1356 and slr1367.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16842345.001).
  • [ISSN] 0378-1097
  • [Journal-full-title] FEMS microbiology letters
  • [ISO-abbreviation] FEMS Microbiol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 9005-79-2 / Glycogen; EC 2.4.1.- / Glycogen Phosphorylase
  •  go-up   go-down


73. Huq S, Sueoka K, Narumi S, Arisaka F, Nakamoto H: Comparative biochemical characterization of two GroEL homologs from the cyanobacterium Synechococcus elongatus PCC 7942. Biosci Biotechnol Biochem; 2010;74(11):2273-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative biochemical characterization of two GroEL homologs from the cyanobacterium Synechococcus elongatus PCC 7942.
  • The chaperone function of cyanobacterial GroELs was examined in vitro for the first time with GroEL1 and GroEL2 of Synechococcus elongatus PCC 7942.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21071850.001).
  • [ISSN] 1347-6947
  • [Journal-full-title] Bioscience, biotechnology, and biochemistry
  • [ISO-abbreviation] Biosci. Biotechnol. Biochem.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Chaperonin 60; 0 / Molecular Chaperones; EC 3.6.1.- / Adenosine Triphosphatases
  •  go-up   go-down


74. Kalina U, Bickhard H, Schulte S: Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract; 2008 Oct;62(10):1614-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemical comparison of seven commercially available prothrombin complex concentrates.
  • AIMS: A number of prothrombin complex concentrates (PCCs) are commercially available but they differ in terms of composition.
  • We performed a series of studies to compare the biochemical properties of seven PCCs.
  • METHODS: The following products were investigated: Beriplex P/N, Octaplex, S-TIM 4, PPSB Solvent Detergent, Uman Complex DI, Kaskadil and Cofact.
  • The thrombin inhibitory capacity of each PCC was determined.
  • RESULTS: The data indicated little difference between most of the products in their levels of factors II, VII, IX and X, with the exception of Uman Complex which had no detectable factor VII.
  • All of the PCCs tested were negative for activated coagulation factors.
  • Purity (i.e. therapeutic protein as a percentage of total protein) was highest in Beriplex P/N, and the second purest product was Uman Complex.
  • CONCLUSION: This in vitro study showed considerable differences between PCCs in terms of coagulation inhibitory capacity and purity.

  • Genetic Alliance. consumer health - Prothrombin.
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691229.001).
  • [ISSN] 1742-1241
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Coagulation Factors; 0 / Blood Proteins; 0 / Protein C; 0 / Protein S; 0 / plasma protein Z; 37224-63-8 / prothrombin complex concentrates; 9005-49-6 / Heparin
  •  go-up   go-down


75. López-Gomollón S, Hernández JA, Wolk CP, Peleato ML, Fillat MF: Expression of furA is modulated by NtcA and strongly enhanced in heterocysts of Anabaena sp. PCC 7120. Microbiology; 2007 Jan;153(Pt 1):42-50
Hazardous Substances Data Bank. IRON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of furA is modulated by NtcA and strongly enhanced in heterocysts of Anabaena sp. PCC 7120.
  • This paper shows that in the diazotrophic cyanobacterium Anabaena sp. strain PCC 7120, levels of furA mRNA and FurA protein increase significantly in response to nitrogen deprivation, and that furA up-regulation takes place specifically in proheterocysts and mature heterocysts.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17185533.001).
  • [ISSN] 1350-0872
  • [Journal-full-title] Microbiology (Reading, England)
  • [ISO-abbreviation] Microbiology (Reading, Engl.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / RNA, Antisense; 0 / RNA, Bacterial; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / Transcription Factors; 0 / ferric uptake regulating proteins, bacterial; E1UOL152H7 / Iron
  •  go-up   go-down


76. van Nederveen FH, Perren A, Dannenberg H, Petri BJ, Dinjens WN, Komminoth P, de Krijger RR: PTEN gene loss, but not mutation, in benign and malignant phaeochromocytomas. J Pathol; 2006 Jun;209(2):274-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The gene is thought to be one of the most frequently mutated tumour suppressor genes and inactivation of PTEN is associated with disease progression and angiogenesis.
  • High vascularization and resistance to chemo- and radio-therapy are two well-established features of phaeochromocytomas (PCCs).
  • Furthermore, benign and malignant PCCs are found in several PTEN knockout mouse models.
  • This study therefore evaluated whether inactivation of PTEN may be involved in the tumourigenesis of PCC in man and whether PTEN abnormalities may help to define the malignant potential of these tumours.
  • Tumour and germline DNA was analysed from 31 patients with apparently sporadic PCC, including 14 clinically benign and 17 malignant tumours, for loss of the PTEN gene locus, mutations in the PTEN gene, and for PTEN protein expression by immunohistochemistry.
  • Loss of heterozygosity (LOH) analysis showed loss of PTEN in four malignant tumours (40%) and in one benign tumour (14%).
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Genes, Tumor Suppressor / physiology. Neoplasm Proteins / genetics. PTEN Phosphohydrolase / genetics. Pheochromocytoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. DNA Mutational Analysis / methods. DNA, Neoplasm / genetics. Female. Gene Silencing / physiology. Humans. Immunohistochemistry / methods. Loss of Heterozygosity / genetics. Male. Middle Aged. Polymorphism, Single-Stranded Conformational

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16538614.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


77. Shimada Y, Tsuchiya T, Akimoto S, Tomo T, Fukuya M, Tanaka K, Mimuro M: Spectral properties of the CP43-deletion mutant of Synechocystis sp. PCC 6803. Photosynth Res; 2008 Oct-Dec;98(1-3):303-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectral properties of the CP43-deletion mutant of Synechocystis sp. PCC 6803.
  • Spectral properties, particularly fluorescence spectra and their time-dependent behavior, were investigated for a mutant of the cyanobacterium Synechocystis sp.
  • PCC 6803 lacking the 43 kDa chlorophyll-protein (CP43, PsbC).
  • [MeSH-major] Bacterial Proteins / genetics. Photosynthetic Reaction Center Complex Proteins / genetics. Photosystem II Protein Complex / physiology. Synechocystis / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18777104.001).
  • [ISSN] 0166-8595
  • [Journal-full-title] Photosynthesis research
  • [ISO-abbreviation] Photosyn. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Photosynthetic Reaction Center Complex Proteins; 0 / Photosystem II Protein Complex; 0 / photosystem II, chlorophyll binding protein, CP-43
  •  go-up   go-down


78. Hampson NB: Trends in the incidence of carbon monoxide poisoning in the United States. Am J Emerg Med; 2005 Nov;23(7):838-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BASIC PROCEDURES: Published data from US poison control centers (PCCs) were used to calculate annual rates of calls regarding carbon monoxide exposures.
  • Trends in rates of carbon monoxide-related mortality, calls to PCCs, and HBO treatment were then compared.
  • MAIN FINDINGS: Contrary to the decline in carbon monoxide-related mortality from 1968 to 1998, rates of calls to PCCs significantly increased over the same period.
  • Neither rates of PCC calls nor HBO treatment changed significantly from 1992 to 2002.
  • [MeSH-minor] Hotlines / trends. Hotlines / utilization. Humans. Hyperbaric Oxygenation / trends. Hyperbaric Oxygenation / utilization. Incidence. Linear Models. Mortality / trends. Poison Control Centers / trends. Poison Control Centers / utilization. Referral and Consultation / trends. Referral and Consultation / utilization. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Carbon Monoxide Poisoning.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16291437.001).
  • [ISSN] 0735-6757
  • [Journal-full-title] The American journal of emergency medicine
  • [ISO-abbreviation] Am J Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Smith MY, Dart R, Hughes A, Geller A, Senay E, Woody G, Colucci S: Clinician validation of Poison Control Center (PCC) intentional exposure cases involving prescription opioids. Am J Drug Alcohol Abuse; 2006;32(3):465-78
MedlinePlus Health Information. consumer health - Prescription Drug Abuse.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinician validation of Poison Control Center (PCC) intentional exposure cases involving prescription opioids.
  • Poison Control Center (PCC) cases involving intentional ingestion, injection or inhalation of prescription opioids are a potentially valuable source of information on the abuse and misuse of these products.
  • This study sought to validate PCC classifications of prescription opioid intentional exposure cases against clinical diagnostic criteria.
  • PCC-clinician concordance was good to excellent for Withdrawal, Abuse, and Suicide (kappa statistics: 0.73, 0.53, 0.48, respectively), but poor for Misuse and Intentional Unknown (Specific motive not known).
  • Results demonstrate the degree of compatibility between PCC and standard nosologic classifications.
  • [MeSH-major] Drug Prescriptions / statistics & numerical data. Intention. Narcotics. Poison Control Centers / statistics & numerical data. Substance-Related Disorders / epidemiology. Surveys and Questionnaires
  • [MeSH-minor] Drug Evaluation, Preclinical. Humans. Observer Variation. Substance Withdrawal Syndrome / epidemiology. Substance Withdrawal Syndrome / etiology. Suicide / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Drug Abuse.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16864474.001).
  • [ISSN] 0095-2990
  • [Journal-full-title] The American journal of drug and alcohol abuse
  • [ISO-abbreviation] Am J Drug Alcohol Abuse
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Narcotics
  •  go-up   go-down


80. Gao Y, Xiong W, Li XB, Gao CF, Zhang YL, Li H, Wu QY: Identification of the proteomic changes in Synechocystis sp. PCC 6803 following prolonged UV-B irradiation. J Exp Bot; 2009;60(4):1141-54

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the proteomic changes in Synechocystis sp. PCC 6803 following prolonged UV-B irradiation.
  • PCC 6803 under short-term and long-term UV-B stress were investigated by using a comparative proteomic approach.
  • The research, showing that short-term response-proteins are quite different from long-term response-proteins, helps to identify the change in homeostatic mechanisms in Synechocystis sp. PCC 6803.
  • PCC 6803 under long-term stress was successfully produced.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261921.001).
  • [ISSN] 1460-2431
  • [Journal-full-title] Journal of experimental botany
  • [ISO-abbreviation] J. Exp. Bot.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Proteome; 1406-65-1 / Chlorophyll; 36-88-4 / Carotenoids; YF5Q9EJC8Y / chlorophyll a
  •  go-up   go-down


81. Ran L, Huang F, Ekman M, Klint J, Bergman B: Proteomic analyses of the photoauto- and diazotrophically grown cyanobacterium Nostoc sp. PCC 73102. Microbiology; 2007 Feb;153(Pt 2):608-18
Hazardous Substances Data Bank. Nitrogen, Elemental .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analyses of the photoauto- and diazotrophically grown cyanobacterium Nostoc sp. PCC 73102.
  • The filamentous cyanobacteria of the genus Nostoc are globally distributed, phenotypically complex organisms, capable of cellular differentiation and of forming symbiotic associations with a wide range of plants.
  • PCC 73102 (N. punctiforme) cells was examined.
  • These observations contribute to our understanding of the complex Nostoc life cycle.
  • [MeSH-minor] Culture Media / chemistry. Gene Expression Regulation, Bacterial. Molecular Sequence Data. Proteomics. Sequence Analysis, DNA. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17259633.001).
  • [ISSN] 1350-0872
  • [Journal-full-title] Microbiology (Reading, England)
  • [ISO-abbreviation] Microbiology (Reading, Engl.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Culture Media; 0 / Proteome; N762921K75 / Nitrogen
  •  go-up   go-down


82. Lamadrid AI, García O, Delbos M, Voisin P, Roy L: PCC-ring induction in human lymphocytes exposed to gamma and neutron irradiation. J Radiat Res; 2007 Jan;48(1):1-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PCC-ring induction in human lymphocytes exposed to gamma and neutron irradiation.
  • Dose-effect relationships were obtained by plotting the frequencies of Premature Chromosome Condensation (PCC)-rings in PCC lymphocytes obtained by chemical induction with Calyculin A in vitro, irradiated with doses between 5 to 25 Gy.
  • For the elaboration of these curves, 9 675 PCC cells in G1 G2 and M/A stages were analysed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102580.001).
  • [ISSN] 0449-3060
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


83. Kondo K, Geng XX, Katayama M, Ikeuchi M: Distinct roles of CpcG1 and CpcG2 in phycobilisome assembly in the cyanobacterium Synechocystis sp. PCC 6803. Photosynth Res; 2005 Jun;84(1-3):269-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct roles of CpcG1 and CpcG2 in phycobilisome assembly in the cyanobacterium Synechocystis sp. PCC 6803.
  • PCC 6803 by gene disruption and fractionation of phycobilisome (sub)complexes.
  • The unique phycocyanin rod-CpcG2 complex without the major allophycocyanin components was isolated from the cpcG1-disruptant.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16049785.001).
  • [ISSN] 0166-8595
  • [Journal-full-title] Photosynthesis research
  • [ISO-abbreviation] Photosyn. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Phycobilisomes
  •  go-up   go-down


84. Aldea MR, Mella-Herrera RA, Golden JW: Sigma factor genes sigC, sigE, and sigG are upregulated in heterocysts of the cyanobacterium Anabaena sp. strain PCC 7120. J Bacteriol; 2007 Nov;189(22):8392-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sigma factor genes sigC, sigE, and sigG are upregulated in heterocysts of the cyanobacterium Anabaena sp. strain PCC 7120.
  • We used gfp transcriptional fusions to investigate the regulation of eight sigma factor genes during heterocyst development in the cyanobacterium Anabaena sp. strain PCC 7120.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Microbiol. 1999 Nov;34(3):473-84 [10564489.001]
  • [Cites] J Bacteriol. 2001 Apr;183(8):2605-13 [11274121.001]
  • [Cites] J Bacteriol. 2001 Nov;183(22):6667-75 [11673438.001]
  • [Cites] Mol Microbiol. 2003 Mar;47(5):1239-49 [12603731.001]
  • [Cites] J Bacteriol. 2003 Aug;185(15):4315-25 [12867439.001]
  • [Cites] Annu Rev Microbiol. 2003;57:441-66 [14527287.001]
  • [Cites] FEBS Lett. 2003 Nov 20;554(3):357-62 [14623094.001]
  • [Cites] Curr Opin Microbiol. 2003 Dec;6(6):557-63 [14662350.001]
  • [Cites] J Bacteriol. 1991 Nov;173(22):7098-105 [1938911.001]
  • [Cites] J Bacteriol. 1992 Nov;174(22):7273-82 [1385387.001]
  • [Cites] Science. 1998 Oct 30;282(5390):935-8 [9794762.001]
  • [Cites] J Biol Chem. 2006 Feb 3;281(5):2668-75 [16303755.001]
  • [Cites] DNA Res. 2007 Feb 28;14(1):13-24 [17376888.001]
  • (PMID = 17873052.001).
  • [ISSN] 1098-5530
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM036890; United States / NIGMS NIH HHS / GM / GM36890
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / DNA-Binding Proteins; 0 / Sigma Factor; 0 / sigC protein, Bacteria; 0 / sigE protein, Bacteria
  • [Other-IDs] NLM/ PMC2168693
  •  go-up   go-down


85. Leganés F, Forchhammer K, Fernández-Piñas F: Role of calcium in acclimation of the cyanobacterium Synechococcus elongatus PCC 7942 to nitrogen starvation. Microbiology; 2009 Jan;155(Pt 1):25-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of calcium in acclimation of the cyanobacterium Synechococcus elongatus PCC 7942 to nitrogen starvation.
  • A Ca2+ signal is required for the process of heterocyst differentiation in the filamentous diazotrophic cyanobacterium Anabaena sp. PCC 7120.
  • This paper presents evidence that a transient increase in intracellular free Ca2+ is also involved in acclimation to nitrogen starvation in the unicellular non-diazotrophic cyanobacterium Synechococcus elongatus PCC 7942.
  • Taken together, the results presented here strongly suggest an involvement of a defined Ca2+ transient in acclimation of S. elongatus to nitrogen starvation through NtcA-dependent regulation.
  • [MeSH-minor] Aequorin / metabolism. Apoproteins / metabolism. Bacterial Proteins / genetics. Bacterial Proteins / metabolism. Calcium-Binding Proteins / metabolism. Culture Media. Heat-Shock Response. Ketoglutaric Acids / metabolism. Mutation. PII Nitrogen Regulatory Proteins / genetics. PII Nitrogen Regulatory Proteins / metabolism. Recombinant Proteins / metabolism. Sulfur / metabolism. Transcription Factors / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. Sulfur, Elemental .
  • Hazardous Substances Data Bank. Nitrogen, Elemental .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19118343.001).
  • [ISSN] 1350-0872
  • [Journal-full-title] Microbiology (Reading, England)
  • [ISO-abbreviation] Microbiology (Reading, Engl.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoproteins; 0 / Bacterial Proteins; 0 / Calcium-Binding Proteins; 0 / Culture Media; 0 / Ketoglutaric Acids; 0 / PII Nitrogen Regulatory Proteins; 0 / Recombinant Proteins; 0 / Transcription Factors; 0 / apoaequorin; 328-50-7 / alpha-ketoglutaric acid; 50934-79-7 / Aequorin; 70FD1KFU70 / Sulfur; N762921K75 / Nitrogen; SY7Q814VUP / Calcium
  •  go-up   go-down


86. Blank A, Schmitt AM, Korpershoek E, van Nederveen F, Rudolph T, Weber N, Strebel RT, de Krijger R, Komminoth P, Perren A: SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling. Endocr Relat Cancer; 2010 Dec;17(4):919-28
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling.
  • Prediction of malignant behaviour of pheochromocytomas/sympathetic paragangliomas (PCCs/PGLs) is very difficult if not impossible on a histopathological basis.
  • In a familial setting, it is well known that succinate dehydrogenase subunit B (SDHB)-associated PCC/PGL very often metastasise.
  • Recently, absence of SDHB expression as measured through immunohistochemistry was shown to be an excellent indicator of the presence of an SDH germline mutation in PCC/PGL.
  • SDHB loss is believed to lead to tumour formation by activation of hypoxia signals.
  • To clarify the potential use of SDHB immunohistochemistry as a marker of malignancy in PCC/PGL and its association with classic hypoxia signalling we examined SDHB, hypoxia inducible factor-1α (Hif-1α) and its targets CA-9 and GLUT-1 expression on protein level using immunohistochemistry on a tissue micro array on a series of familial and sporadic tumours of 115 patients.
  • SDHB protein expression was lost in the tumour tissue of 12 of 99 patients.
  • The lack of correlation of SDHB loss with classic hypoxia signals argues against the current hypoxia hypothesis in malignant PCC/PGL.
  • We suggest SDHB protein loss as a marker of adverse outcome both in sporadic and in familial PCC/PGL.
  • [MeSH-major] Adrenal Gland Neoplasms / enzymology. Pheochromocytoma / enzymology. Succinate Dehydrogenase / deficiency

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20702724.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 9007-49-2 / DNA; EC 1.3.5.1 / SDHB protein, human; EC 1.3.99.1 / Succinate Dehydrogenase
  •  go-up   go-down


87. Lindholm C, Stricklin D, Jaworska A, Koivistoinen A, Paile W, Arvidsson E, Deperas-Standylo J, Wojcik A: Premature chromosome condensation (PCC) assay for dose assessment in mass casualty accidents. Radiat Res; 2010 Jan;173(1):71-8
MedlinePlus Health Information. consumer health - Radiation Emergencies.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Premature chromosome condensation (PCC) assay for dose assessment in mass casualty accidents.
  • The study was undertaken to establish a dose calibration curve for a practical PCC ring assay and to apply it in a simulated mass casualty accident.
  • The PCC assay was validated against the conventional dicentric assay.
  • A linear relationship was established for PCC rings after (60)Co gamma irradiation with doses up to 20 Gy.
  • In the simulated accident experiment, 62 blood samples were analyzed with both the PCC ring assay and the conventional dicentric assay, applying a triage approach.
  • The results indicated that both assays yielded good dose estimates for the whole-body exposure scenario, although in the lower-dose range (0-6 Gy) dicentric scoring resulted in more accurate whole-body estimates, whereas PCC rings were better in the high-dose range (>6 Gy).
  • In conclusion, the study confirmed that the PCC ring assay is suitable for use as a biodosimeter after whole-body exposure to high doses of radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20041761.001).
  • [ISSN] 1938-5404
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


88. Sato M, Nimura-Matsune K, Watanabe S, Chibazakura T, Yoshikawa H: Expression analysis of multiple dnaK genes in the cyanobacterium Synechococcus elongatus PCC 7942. J Bacteriol; 2007 May;189(10):3751-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis of multiple dnaK genes in the cyanobacterium Synechococcus elongatus PCC 7942.
  • We analyzed the stress responses of three dnaK homologues (dnaK1, dnaK2, and dnaK3) in the cyanobacterium Synechococcus elongatus PCC 7942.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plant Physiol. 2000 Apr;122(4):1201-8 [10759516.001]
  • [Cites] Biosci Biotechnol Biochem. 2006 Jul;70(7):1592-8 [16861792.001]
  • [Cites] J Bacteriol. 2001 Feb;183(4):1320-8 [11157945.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):20866-75 [11274153.001]
  • [Cites] J Bacteriol. 2001 Dec;183(24):7318-28 [11717291.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 11;290(1):339-48 [11779175.001]
  • [Cites] Microbiology. 2002 Oct;148(Pt 10):3129-38 [12368446.001]
  • [Cites] FEBS Lett. 2003 Aug 14;549(1-3):57-62 [12914925.001]
  • [Cites] Mol Microbiol. 2003 Oct;50(1):153-66 [14507371.001]
  • [Cites] Plant Physiol. 2004 Oct;136(2):3290-300 [15361582.001]
  • [Cites] Cell. 1983 Sep;34(2):641-6 [6311435.001]
  • [Cites] Annu Rev Genet. 1988;22:631-77 [2853609.001]
  • [Cites] J Bacteriol. 1990 Sep;172(9):5079-88 [1975581.001]
  • [Cites] Genes Dev. 1990 Dec;4(12A):2202-9 [2269429.001]
  • [Cites] Nature. 1992 Jan 2;355(6355):33-45 [1731198.001]
  • [Cites] Mol Gen Genet. 1992 Mar;232(2):221-30 [1372952.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11678-82 [8265608.001]
  • [Cites] Biochem Biophys Res Commun. 1994 May 30;201(1):466-71 [8198610.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Jun 15;201(2):848-54 [8003021.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Dec 4;229(1):334-40 [8954128.001]
  • [Cites] EMBO J. 1997 Aug 1;16(15):4579-90 [9303302.001]
  • [Cites] Plant Mol Biol. 1997 Dec;35(6):763-75 [9426597.001]
  • [Cites] Mol Microbiol. 1998 Jul;29(2):505-13 [9720868.001]
  • [Cites] Microbiology. 1998 Nov;144 ( Pt 11):3097-104 [9846745.001]
  • [Cites] Mol Microbiol. 1999 Jan;31(1):1-8 [9987104.001]
  • [Cites] Mol Microbiol. 1999 Jan;31(1):117-31 [9987115.001]
  • [Cites] Mol Microbiol. 1999 Jan;31(2):521-32 [10027969.001]
  • [Cites] Mol Microbiol. 1999 May;32(3):581-93 [10320580.001]
  • [Cites] Plant Mol Biol. 1999 Jun;40(3):409-18 [10437825.001]
  • [Cites] Microbiology. 1999 Sep;145 ( Pt 9):2385-91 [10517591.001]
  • [Cites] J Biol Chem. 2004 Dec 17;279(51):53078-86 [15471853.001]
  • [Cites] J Biol Chem. 2005 Jun 3;280(22):21531-8 [15805106.001]
  • [Cites] Plant Physiol. 2005 Jul;138(3):1409-21 [15965020.001]
  • [Cites] Curr Microbiol. 2005 Sep;51(3):164-70 [16059771.001]
  • [Cites] Proteomics. 2006 Feb;6(3):845-64 [16400687.001]
  • [Cites] Plant Physiol. 2000 Jul;123(3):1047-56 [10889254.001]
  • (PMID = 17351044.001).
  • [ISSN] 0021-9193
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / DnaK3 protein, Synechococcus; 0 / HSP70 Heat-Shock Proteins; 0 / Membrane Proteins; 0 / RNA, Bacterial
  • [Other-IDs] NLM/ PMC1913318
  •  go-up   go-down


89. Toyoshima M, Sasaki NV, Fujiwara M, Ehira S, Ohmori M, Sato N: Early candidacy for differentiation into heterocysts in the filamentous cyanobacterium Anabaena sp. PCC 7120. Arch Microbiol; 2010 Jan;192(1):23-31
Hazardous Substances Data Bank. Nitrogen, Elemental .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early candidacy for differentiation into heterocysts in the filamentous cyanobacterium Anabaena sp. PCC 7120.
  • PCC 7120 fixes dinitrogen facultatively.
  • Such early candidacy could be explained by different properties of the outer and inner cells of a quartet, but the molecular nature of candidacy remains to be uncovered.
  • [MeSH-minor] Amino Acid Sequence. Bacterial Proteins / genetics. Bacterial Proteins / metabolism. Bacterial Proteins / physiology. Culture Media / metabolism. Fluorescence. Gene Deletion. Gene Dosage. Gene Expression Regulation, Bacterial. Gene Expression Regulation, Developmental. Gene Silencing. Genes, Bacterial. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Microscopy, Fluorescence. Models, Biological. Multigene Family. Mutation. Nitrogen / metabolism. Nitrogen Fixation / genetics. Phencyclidine / analogs & derivatives. Phencyclidine / metabolism. Promoter Regions, Genetic. Sequence Alignment

  • Hazardous Substances Data Bank. PHENCYCLIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19911166.001).
  • [ISSN] 1432-072X
  • [Journal-full-title] Archives of microbiology
  • [ISO-abbreviation] Arch. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Culture Media; 03ZI7ZZW5Q / 1-piperidinocyclohexanecarbonitrile; 147336-22-9 / Green Fluorescent Proteins; J1DOI7UV76 / Phencyclidine; N762921K75 / Nitrogen
  •  go-up   go-down


90. Holtzendorff J, Partensky F, Mella D, Lennon JF, Hess WR, Garczarek L: Genome streamlining results in loss of robustness of the circadian clock in the marine cyanobacterium Prochlorococcus marinus PCC 9511. J Biol Rhythms; 2008 Jun;23(3):187-99

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome streamlining results in loss of robustness of the circadian clock in the marine cyanobacterium Prochlorococcus marinus PCC 9511.
  • Using quantitative real-time PCR, we show here that in Prochlorococcus marinus PCC 9511, the mRNA levels of the clock genes kaiB and kaiC, as well as a few other selected genes including psbA, also displayed marked diel variations when cultures were kept under a light-dark rhythm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487411.001).
  • [ISSN] 0748-7304
  • [Journal-full-title] Journal of biological rhythms
  • [ISO-abbreviation] J. Biol. Rhythms
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Trans-Activators; EC 2.3.1.48 / CLOCK Proteins
  •  go-up   go-down


91. Srivastava R, Pisareva T, Norling B: Proteomic studies of the thylakoid membrane of Synechocystis sp. PCC 6803. Proteomics; 2005 Dec;5(18):4905-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic studies of the thylakoid membrane of Synechocystis sp. PCC 6803.
  • PCC 6803 were used for the first time in proteomic studies.
  • Among the proteins identified were subunits of the well-characterized thylakoid membrane constituents Photosystem I and II, ATP synthase, cytochrome b6f-complex, NADH dehydrogenase, and phycobilisome complex.
  • Interestingly, in view of the protein sorting mechanism in cyanobacteria, one of the two signal peptidases type I of Synechocystis was found in the thylakoid membrane, whereas the second one has been identified previously in the plasma membrane.
  • [MeSH-minor] Chloroplast Proton-Translocating ATPases / biosynthesis. Cytochrome b6f Complex / biosynthesis. Electrophoresis, Gel, Two-Dimensional / methods. Electrophoresis, Polyacrylamide Gel. NADH Dehydrogenase / biosynthesis. Photosynthetic Reaction Center Complex Proteins / biosynthesis. Pigments, Biological / biosynthesis. Protein Folding. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16287171.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Photosynthetic Reaction Center Complex Proteins; 0 / Pigments, Biological; 0 / Proteome; 9035-40-9 / Cytochrome b6f Complex; EC 1.6.99.3 / NADH Dehydrogenase; EC 3.6.3.- / Chloroplast Proton-Translocating ATPases
  •  go-up   go-down


92. Suzuki E, Umeda K, Nihei S, Moriya K, Ohkawa H, Fujiwara S, Tsuzuki M, Nakamura Y: Role of the GlgX protein in glycogen metabolism of the cyanobacterium, Synechococcus elongatus PCC 7942. Biochim Biophys Acta; 2007 May;1770(5):763-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the GlgX protein in glycogen metabolism of the cyanobacterium, Synechococcus elongatus PCC 7942.
  • The putative glgX gene encoding isoamylase-type debranching enzyme was isolated from the cyanobacterium, Synechococcus elongatus PCC 7942.
  • The deduced amino acid sequence indicated that the residues essential to the catalytic activity and substrate binding in bacterial and plant isoamylases and GlgX proteins were all conserved in the GlgX protein of S. elongatus PCC 7942.
  • Disruption of the glgX gene resulted in the enhanced fluctuation of glycogen content in the cells during light-dark cycles of the culture, although the effect was marginal.
  • PCC 6803, the short chains were decreased as compared to the parental mutant strain.
  • The result indicated that GlgX protein contributes to form the branching pattern of polysaccharide in S. elongatus PCC 7942.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17321685.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / DNA, Bacterial; 9005-79-2 / Glycogen; EC 3.2.1.68 / Isoamylase
  •  go-up   go-down


93. Bier SA, Borys DJ: Emergency medical services' use of poison control centers for unintentional drug ingestions. Am J Emerg Med; 2010 Oct;28(8):911-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emergency medical services' use of poison control centers for unintentional drug ingestions.
  • Many systems have begun using poison control centers (PCCs) when unsure of disposition.
  • We sought to determine the type of exposures EMS personnel were using the PCCs for and treatments suggested.
  • Secondary end points included transport rate after consulting the PCC and amount of money saved by avoiding unnecessary transports.
  • In only 6% of cases did the PCC recommend administration of medication.
  • This study suggests that the use of PCCs by EMS systems can be beneficial to patient care.
  • For the time period of this study, EMS crews who contacted the PCC saved the City of Austin more than $205,000 in unnecessary ambulance transport costs.
  • This modality is an important resource for providers in a potentially uncertain realm.
  • [MeSH-major] Emergency Medical Services / statistics & numerical data. Poison Control Centers / utilization. Poisoning / diagnosis

  • MedlinePlus Health Information. consumer health - Emergency Medical Services.
  • MedlinePlus Health Information. consumer health - Poisoning.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20825923.001).
  • [ISSN] 1532-8171
  • [Journal-full-title] The American journal of emergency medicine
  • [ISO-abbreviation] Am J Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations
  •  go-up   go-down


94. Peca L, Kós PB, Vass I: Characterization of the activity of heavy metal-responsive promoters in the cyanobacterium Synechocystis PCC 6803. Acta Biol Hung; 2007;58 Suppl:11-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of the activity of heavy metal-responsive promoters in the cyanobacterium Synechocystis PCC 6803.
  • Aiming at developing cyanobacterial-based biosensors for heavy metal detection, expression of heavy metal inducible genes of the cyanobacterium Synechocystis PCC 6803 was investigated by quantitative RT-PCR upon 15 minutes exposure to biologically relevant concentrations of Co2+, Zn2+, Ni2+, Cd2+, Cr6+, As3+ and As5+.
  • Expression of nrsB, which encodes a part of a putative Ni2+ efflux system was highly induced by Ni2+ salts and at a low extent by Co2+ and Zn2+ salts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297791.001).
  • [ISSN] 0236-5383
  • [Journal-full-title] Acta biologica Hungarica
  • [ISO-abbreviation] Acta. Biol. Hung.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Metals, Heavy
  •  go-up   go-down


95. Jähnichen S, Ihle T, Petzoldt T, Benndorf J: Impact of inorganic carbon availability on microcystin production by Microcystis aeruginosa PCC 7806. Appl Environ Microbiol; 2007 Nov;73(21):6994-7002
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of inorganic carbon availability on microcystin production by Microcystis aeruginosa PCC 7806.
  • Batch culture experiments with the cyanobacterium Microcystis aeruginosa PCC 7806 were performed in order to test the hypothesis that microcystins (MCYSTs) are produced in response to a relative deficiency of intracellular inorganic carbon (C(i,i)).
  • The same experimental approach was used in a second experiment to compare the response of the wild-type strain M. aeruginosa PCC 7806 with its mcyB mutant, which lacks the ability to produce MCYSTs.
  • In a third experiment, the impact of varying the C(i,i) status on MCYST production was examined without suppressing the sodium-dependent bicarbonate transporter; instead, a detailed investigation of a dark-light cycle was performed.
  • [MeSH-major] Carbon Compounds, Inorganic / metabolism. Microcystins / metabolism. Microcystis / metabolism. Peptides, Cyclic / biosynthesis
  • [MeSH-minor] Gene Expression Regulation, Bacterial. Photosynthetic Reaction Center Complex Proteins / metabolism. Phycocyanin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13571-6 [10557362.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2006 Jun 29;361(1470):969-1006 [16754610.001]
  • [Cites] Appl Environ Microbiol. 2000 Aug;66(8):3387-92 [10919796.001]
  • [Cites] Chem Biol. 2000 Oct;7(10):753-64 [11033079.001]
  • [Cites] Appl Environ Microbiol. 2001 Jan;67(1):278-83 [11133456.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):4817-8 [11320226.001]
  • [Cites] Microbiology. 2001 Nov;147(Pt 11):3113-9 [11700361.001]
  • [Cites] Appl Environ Microbiol. 2003 Mar;69(3):1475-81 [12620831.001]
  • [Cites] J Biotechnol. 2003 Apr 10;102(1):55-9 [12668314.001]
  • [Cites] J Chromatogr A. 2003 Dec 5;1020(1):105-19 [14661762.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):568-73 [14701903.001]
  • [Cites] Appl Environ Microbiol. 2004 Aug;70(8):4551-60 [15294785.001]
  • [Cites] Plant Physiol. 2004 Oct;136(2):3301-12 [15466225.001]
  • [Cites] Eur Biophys J. 1995;24(2):69-76 [8582320.001]
  • [Cites] Appl Environ Microbiol. 1997 Jun;63(6):2206-12 [9172340.001]
  • [Cites] Mol Microbiol. 1997 Nov;26(4):779-87 [9427407.001]
  • [Cites] Appl Environ Microbiol. 2004 Nov;70(11):6370-8 [15528494.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jan 21;326(3):687-94 [15596154.001]
  • [Cites] J Struct Biol. 2005 Aug;151(2):208-14 [16054393.001]
  • [Cites] Plant Physiol. 2005 Dec;139(4):1959-69 [16306144.001]
  • [Cites] J Exp Bot. 2006;57(2):249-65 [16216846.001]
  • [Cites] Mol Microbiol. 2006 Feb;59(3):893-906 [16420359.001]
  • [Cites] Toxicon. 2006 Feb;47(2):218-28 [16376961.001]
  • [Cites] Appl Environ Microbiol. 2000 Jan;66(1):176-9 [10618220.001]
  • (PMID = 17827326.001).
  • [ISSN] 0099-2240
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Compounds, Inorganic; 0 / Microcystins; 0 / Peptides, Cyclic; 0 / Photosynthetic Reaction Center Complex Proteins; 11016-15-2 / Phycocyanin; 77238-39-2 / microcystin
  • [Other-IDs] NLM/ PMC2074933
  •  go-up   go-down


96. Maheswaran M, Ziegler K, Lockau W, Hagemann M, Forchhammer K: PII-regulated arginine synthesis controls accumulation of cyanophycin in Synechocystis sp. strain PCC 6803. J Bacteriol; 2006 Apr;188(7):2730-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PII-regulated arginine synthesis controls accumulation of cyanophycin in Synechocystis sp. strain PCC 6803.
  • The cyanobacterium Synechocystis sp. strain PCC 6803 accumulates cyanophycin following a transition from nitrogen-limited to nitrogen-excess conditions.

  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bacteriol. 1995 Oct;177(20):5812-7 [7592328.001]
  • [Cites] J Biol Chem. 1995 Jul 28;270(30):17797-807 [7629080.001]
  • [Cites] Microbiology. 1998 Jun;144 ( Pt 6):1537-47 [9639924.001]
  • [Cites] Eur J Biochem. 1998 May 15;254(1):154-9 [9652408.001]
  • [Cites] Eur J Biochem. 1999 Jul;263(1):163-9 [10429200.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55202-10 [15502156.001]
  • [Cites] Plant Cell Physiol. 2004 Dec;45(12):1768-78 [15653795.001]
  • [Cites] Plant Biol (Stuttg). 2005 Jan;7(1):15-22 [15666206.001]
  • [Cites] Microbiology. 2005 Apr;151(Pt 4):1275-83 [15817794.001]
  • [Cites] FEMS Microbiol Lett. 1999 Dec 15;181(2):229-36 [10585543.001]
  • [Cites] FEBS Lett. 1999 Dec 17;463(3):216-20 [10606724.001]
  • [Cites] J Bacteriol. 2000 Feb;182(4):1008-15 [10648527.001]
  • [Cites] Eur J Biochem. 2000 Sep;267(17):5561-70 [10951215.001]
  • [Cites] Arch Microbiol. 2000 Nov;174(5):297-306 [11131019.001]
  • [Cites] Z Naturforsch C. 2000 Nov-Dec;55(11-12):927-42 [11204198.001]
  • [Cites] Microbiol Mol Biol Rev. 2001 Mar;65(1):80-105 [11238986.001]
  • [Cites] Appl Environ Microbiol. 2001 May;67(5):2176-82 [11319097.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):12978-83 [11687619.001]
  • [Cites] Arch Microbiol. 2002 May;177(5):371-80 [11976746.001]
  • [Cites] Biochem J. 2002 May 15;364(Pt 1):129-36 [11988085.001]
  • [Cites] Mol Microbiol. 2002 May;44(3):855-64 [11994164.001]
  • [Cites] Naturwissenschaften. 2002 Jan;89(1):11-22 [12008968.001]
  • [Cites] Z Naturforsch C. 2002 May-Jun;57(5-6):522-9 [12132696.001]
  • [Cites] Biochem J. 2003 Jun 1;372(Pt 2):279-90 [12633501.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11582-92 [14679189.001]
  • [Cites] J Bacteriol. 2004 Jun;186(11):3346-54 [15150219.001]
  • [Cites] Mol Microbiol. 2004 Jun;52(5):1225-8 [15165227.001]
  • [Cites] Mol Microbiol. 2004 Jun;52(5):1303-14 [15165234.001]
  • [Cites] Microbiology. 2004 Aug;150(Pt 8):2599-608 [15289556.001]
  • [Cites] FEMS Microbiol Rev. 2004 Jun;28(3):319-33 [15449606.001]
  • [Cites] FEBS Lett. 2004 Oct 8;576(1-2):261-5 [15474048.001]
  • [Cites] J Bacteriol. 1973 Jun;114(3):1213-6 [4197270.001]
  • [Cites] Arch Mikrobiol. 1973;92(2):115-22 [4200161.001]
  • [Cites] Biochim Biophys Acta. 1976 Jan 20;420(1):165-76 [813773.001]
  • [Cites] J Biol Chem. 2005 Oct 14;280(41):34684-90 [16109709.001]
  • [Cites] Biochim Biophys Acta. 1976 Feb 13;422(2):407-18 [2311.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Bacteriol. 1980 Feb;141(2):687-93 [6767688.001]
  • [Cites] Annu Rev Microbiol. 1984;38:1-25 [6437321.001]
  • [Cites] J Bacteriol. 1987 Oct;169(10):4668-73 [3115962.001]
  • [Cites] Methods Enzymol. 1988;167:3-27 [3148836.001]
  • [Cites] Eur J Biochem. 1997 Mar 15;244(3):869-75 [9108259.001]
  • (PMID = 16547064.001).
  • [ISSN] 0021-9193
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / PII Nitrogen Regulatory Proteins; 0 / Plant Proteins; 0 / cyanophycin; 94ZLA3W45F / Arginine
  • [Other-IDs] NLM/ PMC1428389
  •  go-up   go-down


97. Kurian D, Jansèn T, Mäenpää P: Proteomic analysis of heterotrophy in Synechocystis sp. PCC 6803. Proteomics; 2006 Mar;6(5):1483-94
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of heterotrophy in Synechocystis sp. PCC 6803.
  • To provide an insight into the heterotrophic metabolism of cyanobacteria, a proteomic approach has been employed with the model organism Synechocystis sp. PCC 6803.
  • The soluble proteins from Synechocystis grown under photoautotrophic and light-activated heterotrophic conditions were separated by 2-DE and identified by MALDI-MS or LC-MS/MS analysis.
  • 2-DE gels made using narrow- and micro-range IPG strips allowed quantitative comparison of more than 900 spots.
  • Alterations in the expression level of proteins involved in carbon utilization pathways refer to enhanced glycolysis, oxidative pentose phosphate pathway as well as tricarboxylic acid cycle under heterotrophy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16421936.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Bacterial Proteins; 0 / Proteome; S88TT14065 / Oxygen
  •  go-up   go-down


98. Li G, Tang Z, Meng G, Dai K, Zhao J, Zheng X: Crystallization and preliminary X-ray crystallographic studies of O-methyltransferase from Anabaena PCC 7120. Acta Crystallogr Sect F Struct Biol Cryst Commun; 2009 Oct 1;65(Pt 10):1039-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crystallization and preliminary X-ray crystallographic studies of O-methyltransferase from Anabaena PCC 7120.
  • To investigate the structure and function of OMTs, omt from Anabaena PCC 7120 was cloned into expression vector pET21a and expressed in a soluble form in Escherichia coli strain BL21 (DE3).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Crystallogr D Biol Crystallogr. 1999 Oct;55(Pt 10):1690-5 [10531518.001]
  • [Cites] J Biol Chem. 2008 Jul 25;283(30):20888-96 [18502765.001]
  • [Cites] J Org Chem. 2000 Dec 1;65(24):8127-33 [11101363.001]
  • [Cites] Curr Drug Metab. 2002 Jun;3(3):321-49 [12083324.001]
  • [Cites] Plant Cell. 2002 Jun;14(6):1265-77 [12084826.001]
  • [Cites] Cell. 2002 Oct 4;111(1):91-103 [12372303.001]
  • [Cites] Cell. 2002 Oct 4;111(1):105-15 [12372304.001]
  • [Cites] Cell. 2002 Oct 4;111(1):117-27 [12372305.001]
  • [Cites] Nat Struct Biol. 2002 Nov;9(11):828-32 [12389037.001]
  • [Cites] Nat Struct Biol. 2002 Nov;9(11):833-8 [12389038.001]
  • [Cites] Phytochemistry. 2003 Jan;62(1):53-65 [12475619.001]
  • [Cites] Curr Opin Struct Biol. 2002 Dec;12(6):783-93 [12504684.001]
  • [Cites] J Biol Chem. 2003 Nov 7;278(45):43961-72 [12941960.001]
  • [Cites] Arch Biochem Biophys. 1989 Jun;271(2):488-94 [2499260.001]
  • [Cites] J Mol Biol. 1995 Mar 17;247(1):16-20 [7897657.001]
  • [Cites] Plant J. 2006 Apr;46(2):193-205 [16623883.001]
  • [Cites] J Microbiol Biotechnol. 2007 Feb;17(2):369-72 [18051771.001]
  • [Cites] J Mol Biol. 2008 Apr 18;378(1):154-64 [18342334.001]
  • [Cites] Pharmacol Rev. 1999 Dec;51(4):593-628 [10581325.001]
  • (PMID = 19851017.001).
  • [ISSN] 1744-3091
  • [Journal-full-title] Acta crystallographica. Section F, Structural biology and crystallization communications
  • [ISO-abbreviation] Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.1.1.- / Methyltransferases
  • [Other-IDs] NLM/ PMC2765896
  •  go-up   go-down


99. Rasch B, Dodt C, Mölle M, Born J: Sleep-stage-specific regulation of plasma catecholamine concentration. Psychoneuroendocrinology; 2007 Sep-Nov;32(8-10):884-91
Hazardous Substances Data Bank. EPINEPHRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sleep-stage-specific regulation of plasma catecholamine concentration.
  • It is not yet clear whether blood catecholamine concentrations (as a measure of sympathetic activity in the body periphery) show a similar sleep stage-dependent decline or depend mainly on a circadian rhythm.
  • Here, we show that during sleep in humans, plasma concentrations of norepinephrine (NE) and epinephrine (E) exhibit a progressive decline associated with the stage of sleep, irrespective of the circadian time of sleep.
  • Plasma catecholamine concentrations distinctly declined in a linear fashion as sleep deepened, reaching a minimum during REM sleep both during daytime and nighttime sleep.
  • Because the changes observed here in human blood catecholamine levels closely mimic the changes in brain catecholamine activity, as well-documented in animals, we suggest that the organism's overall catecholamine activity during sleep is well represented by measures of plasma catecholamine concentrations.

  • Hazardous Substances Data Bank. Norepinephrine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651907.001).
  • [ISSN] 0306-4530
  • [Journal-full-title] Psychoneuroendocrinology
  • [ISO-abbreviation] Psychoneuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] X4W3ENH1CV / Norepinephrine; YKH834O4BH / Epinephrine
  •  go-up   go-down


100. Zeng WL, Zhao FF, Cao ZG, Ru BG: [Decontamination of heavy metals in wastewater by transgenic Synechococcus sp. PCC 7002 with mouse metallothionein-I gene]. Huan Jing Ke Xue; 2008 Mar;29(3):738-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Decontamination of heavy metals in wastewater by transgenic Synechococcus sp. PCC 7002 with mouse metallothionein-I gene].
  • PCC 7002 with mouse metallothionein-I gene were studied.
  • PCC 7002 not only has a higher tolerance to heavy metals, but also has a higher growth rate than wild strain.
  • The concentration of Cd2+, Pb2+ and Hg2+ decreases with the progress of cultivation, and its maximum decreasing extent occurs at 1 - 3 day.
  • PCC 7002 is 10.75, 58.89 and 112.61 mg g(-1) of dried cells respectively, which is 3.16, 2.18 and 100.45 times higher than wild cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649537.001).
  • [ISSN] 0250-3301
  • [Journal-full-title] Huan jing ke xue= Huanjing kexue
  • [ISO-abbreviation] Huan Jing Ke Xue
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Metals, Heavy; 9038-94-2 / Metallothionein
  •  go-up   go-down






Advertisement